{
  "$schema": "folio-library-document/v1",
  "id": "10665-331525",
  "title": "WHO operational handbook on tuberculosis: module 1: prevention: tuberculosis preventive treatment",
  "variant": "pdf",
  "pages": 140,
  "tocSource": "outline",
  "tocMethod": null,
  "toc": [
    {
      "level": 1,
      "title": "Acknowledgements",
      "number": null,
      "page": 6,
      "pageLabel": "iv",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-000-acknowledgements"
    },
    {
      "level": 2,
      "title": "Abbreviations & acronyms",
      "number": null,
      "page": 8,
      "pageLabel": "vi",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-001-abbreviations-acronyms"
    },
    {
      "level": 2,
      "title": "Definitions",
      "number": null,
      "page": 10,
      "pageLabel": "viii",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-002-definitions"
    },
    {
      "level": 2,
      "title": "Chapter 1. Introduction and approach",
      "number": null,
      "page": 13,
      "pageLabel": "2",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-003-chapter-1-introduction-and-approach"
    },
    {
      "level": 2,
      "title": "Chapter 2. Identification of populations for TB preventive treatment",
      "number": null,
      "page": 19,
      "pageLabel": "8",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-004-chapter-2-identification-of-populations-for-tb-p"
    },
    {
      "level": 2,
      "title": "Chapter 3. Ruling out TB disease before TB preventive treatment",
      "number": null,
      "page": 31,
      "pageLabel": "20",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-005-chapter-3-ruling-out-tb-disease-before-tb-preven"
    },
    {
      "level": 2,
      "title": "Chapter 4. Testing for TB infection",
      "number": null,
      "page": 39,
      "pageLabel": "28",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-006-chapter-4-testing-for-tb-infection"
    },
    {
      "level": 2,
      "title": "Chapter 5. TB preventive treatment",
      "number": null,
      "page": 47,
      "pageLabel": "36",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-007-chapter-5-tb-preventive-treatment"
    },
    {
      "level": 2,
      "title": "Chapter 6. Safety, management of adverse reactions and other drug-related issues in TB preventive treatment",
      "number": null,
      "page": 67,
      "pageLabel": "56",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-008-chapter-6-safety-management-of-adverse-reactions"
    },
    {
      "level": 2,
      "title": "Chapter 7. Adherence to TB preventive treatment",
      "number": null,
      "page": 83,
      "pageLabel": "72",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-009-chapter-7-adherence-to-tb-preventive-treatment"
    },
    {
      "level": 2,
      "title": "Chapter 8. Monitoring and evaluation",
      "number": null,
      "page": 93,
      "pageLabel": "82",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-010-chapter-8-monitoring-and-evaluation"
    },
    {
      "level": 2,
      "title": "Chapter 9. Ethics and TB preventive treatment",
      "number": null,
      "page": 103,
      "pageLabel": "92",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-011-chapter-9-ethics-and-tb-preventive-treatment"
    },
    {
      "level": 2,
      "title": "Annex 1. List of key messages",
      "number": null,
      "page": 106,
      "pageLabel": "95",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-012-annex-1-list-of-key-messages"
    },
    {
      "level": 2,
      "title": "Annex 2. Coordination mechanisms to support PMTPT",
      "number": null,
      "page": 116,
      "pageLabel": "105",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-013-annex-2-coordination-mechanisms-to-support-pmtpt"
    },
    {
      "level": 2,
      "title": "Annex 3. Costing considerations for programmatic management of TB preventive treatment",
      "number": null,
      "page": 118,
      "pageLabel": "107",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-014-annex-3-costing-considerations-for-programmatic"
    },
    {
      "level": 2,
      "title": "Annex 4. Planning checklist for PMTPT",
      "number": null,
      "page": 120,
      "pageLabel": "109",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-015-annex-4-planning-checklist-for-pmtpt"
    },
    {
      "level": 2,
      "title": "Annex 5. Answers to frequently asked questions on TST",
      "number": null,
      "page": 122,
      "pageLabel": "111",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-016-annex-5-answers-to-frequently-asked-questions-on"
    },
    {
      "level": 2,
      "title": "Annex 6. Answers to frequently asked questions on IGRAs",
      "number": null,
      "page": 127,
      "pageLabel": "116",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-017-annex-6-answers-to-frequently-asked-questions-on"
    },
    {
      "level": 2,
      "title": "References",
      "number": null,
      "page": 130,
      "pageLabel": "119",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-018-references"
    }
  ],
  "sections": [
    {
      "id": "sec-front-matter",
      "number": null,
      "title": "Front matter",
      "level": 1,
      "pageStart": 1,
      "pageEnd": 6,
      "labelStart": "a",
      "labelEnd": "iv",
      "words": 673,
      "summary": {
        "text": "The front matter of the WHO operational handbook on tuberculosis preventive treatment (Module 1: Prevention), with title pages, ISBNs, the CC BY-NC-SA licence and disclaimers. It then gives the table of contents, running from the introduction through chapters on target populations, ruling out disease, testing, regimens and safety to annexes on planning and frequently asked questions about TST and IGRAs.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tuberculosis preventive",
          "heading": false
        },
        {
          "term": "preventive treatment",
          "heading": false
        },
        {
          "term": "operational handbook",
          "heading": false
        },
        {
          "term": "prevention tuberculosis",
          "heading": false
        },
        {
          "term": "creative commons",
          "heading": false
        },
        {
          "term": "suggested citation",
          "heading": false
        },
        {
          "term": "licence",
          "heading": false
        },
        {
          "term": "asked questions",
          "heading": false
        }
      ],
      "extract": "WHO operational handbook on tuberculosis Module 1: Prevention Tuberculosis preventive treatment WHO operational handbook on tuberculosis Module 1: Prevention Tuberculosis preventive treatment WHO operational handbook on tuberculosis. Module 1: prevention - tuberculosis preventive treatment ISBN 978-92-4-000290-6 (electronic version) ISBN 978-92-4-000291-3 (print version) © World Health Organization 2020 Some rights",
      "extractCut": true,
      "blocks": [
        "library/10665-331525/blocks/prose-sec-front-matter"
      ]
    },
    {
      "id": "sec-000-acknowledgements",
      "number": null,
      "title": "Acknowledgements",
      "level": 1,
      "pageStart": 6,
      "pageEnd": 8,
      "labelStart": "iv",
      "labelEnd": "vi",
      "words": 774,
      "summary": {
        "text": "Acknowledges the people behind the TB preventive treatment handbook, including its lead author and WHO Global TB Programme staff. It names the members, co-chairs and observers of the 2020 Guideline Development Group and the External Review Group. It also credits partners who supplied materials and notes that Unitaid funded design and layout.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "nandi siegfried",
          "heading": false
        },
        {
          "term": "lindiwe mvusi",
          "heading": false
        },
        {
          "term": "yohhei hamada",
          "heading": false
        },
        {
          "term": "south africa",
          "heading": false
        },
        {
          "term": "tropical medicine",
          "heading": false
        },
        {
          "term": "infectious diseases",
          "heading": false
        },
        {
          "term": "guideline revision",
          "heading": false
        },
        {
          "term": "london school",
          "heading": false
        }
      ],
      "extract": "This operational handbook was prepared by Avinash Kanchar with inputs from Dennis Falzon and Matteo Zignol under the overall direction of Tereza Kasaeva, Director of the WHO Global TB Programme. The WHO Global TB Programme gratefully acknowledges the contributions of all experts and reviewers involved in the production of the latest update of the WHO guidelines on TB preventive treatment on which this handbook is",
      "extractCut": true
    },
    {
      "id": "sec-001-abbreviations-acronyms",
      "number": null,
      "title": "Abbreviations & acronyms",
      "level": 2,
      "pageStart": 8,
      "pageEnd": 10,
      "labelStart": "vi",
      "labelEnd": "viii",
      "words": 334,
      "summary": {
        "text": "A list of abbreviations and acronyms used in the TB preventive treatment handbook, covering regimens such as 3HP and 1HP, antiretroviral drugs, tests and programme terms.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "isoniazid monotherapy",
          "heading": false
        },
        {
          "term": "transcriptase inhibitor",
          "heading": false
        },
        {
          "term": "plus isoniazid",
          "heading": false
        },
        {
          "term": "reverse transcriptase",
          "heading": false
        },
        {
          "term": "tuberculosis preventive",
          "heading": false
        },
        {
          "term": "rifapentine plus",
          "heading": false
        },
        {
          "term": "preventive treatment",
          "heading": false
        },
        {
          "term": "diphosphate",
          "heading": false
        }
      ],
      "extract": "1HP one month of daily rifapentine plus isoniazid 3HP three months of weekly rifapentine plus isoniazid 3HR three months of daily rifampicin plus isoniazid 3TC lamivudine 4R four months of daily rifampicin monotherapy 6H six months of daily isoniazid monotherapy 9H nine months of daily isoniazid monotherapy ABC abacavir ACF active TB case finding AIDS acquired immunodeficiency syndrome ALT alanine aminotransferase",
      "extractCut": true
    },
    {
      "id": "sec-002-definitions",
      "number": null,
      "title": "Definitions",
      "level": 2,
      "pageStart": 10,
      "pageEnd": 13,
      "labelStart": "viii",
      "labelEnd": "2",
      "words": 823,
      "summary": {
        "text": "Defines key terms used in the TB preventive treatment handbook, such as age groups, contact, household and close contact, index patient, high transmission setting and latent TB infection. Further definitions cover programmatic management, screening and treatment completion. It closes with a call to deliver preventive treatment to 30 million people by 2022 in line with the UN high-level meeting commitments.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "contact investigation",
          "heading": false
        },
        {
          "term": "preventive treatment",
          "heading": false
        },
        {
          "term": "tuberculosis infection",
          "heading": false
        },
        {
          "term": "index patient",
          "heading": false
        },
        {
          "term": "systematic screening",
          "heading": false
        },
        {
          "term": "periods during",
          "heading": false
        },
        {
          "term": "ltbi",
          "heading": false
        },
        {
          "term": "definitions",
          "heading": true
        }
      ],
      "extract": "Note: Unless otherwise specified, the definitions listed below apply to the terms as used in this handbook. They may have different meanings in other contexts. Active case finding (ACF): is synonymous with systematic screening for TB disease, although it normally implies screening that is implemented outside of health facilities. Adolescent: is a person aged 10–19 years. Adult: is a person over 19 years of age.",
      "extractCut": true
    },
    {
      "id": "sec-003-chapter-1-introduction-and-approach",
      "number": null,
      "title": "Chapter 1. Introduction and approach",
      "level": 2,
      "pageStart": 13,
      "pageEnd": 19,
      "labelStart": "2",
      "labelEnd": "8",
      "words": 2502,
      "summary": {
        "text": "Introduces the TB preventive treatment handbook, explaining that about a quarter of people worldwide are infected with M. tuberculosis and that people with HIV and contacts of TB patients are at highest risk. It places programmatic management of preventive treatment within the End TB Strategy and the 2018 UN high-level meeting targets, noting low coverage so far. It describes the handbook's purpose, intended users and approach of guiding countries through decision points. A box summarises WHO recommendations and urges governments and donors to expand access.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tpt among",
          "heading": false
        },
        {
          "term": "shorter tpt",
          "heading": false
        },
        {
          "term": "tpt services",
          "heading": false
        },
        {
          "term": "tpt regimens",
          "heading": false
        },
        {
          "term": "preventive treatment",
          "heading": false
        },
        {
          "term": "household contacts",
          "heading": false
        },
        {
          "term": "offered preventive",
          "heading": false
        },
        {
          "term": "contacts aged",
          "heading": false
        }
      ],
      "extract": "Introduction and approach Introduction About one fourth of the world’s population is estimated to be infected with M. tuberculosis (1,2). The risk of TB disease after infection depends on several factors, the most important being weakened immunological status (3). The vast majority of infected individuals show no signs or symptoms of TB and are not infectious, although they have an increased risk of progressing to",
      "extractCut": true
    },
    {
      "id": "sec-004-chapter-2-identification-of-populations-for-tb-p",
      "number": null,
      "title": "Chapter 2. Identification of populations for TB preventive treatment",
      "level": 2,
      "pageStart": 19,
      "pageEnd": 31,
      "labelStart": "8",
      "labelEnd": "20",
      "words": 4937,
      "summary": {
        "text": "Discusses which at-risk populations countries should prioritise for systematic testing and TB preventive treatment, based on infection prevalence, progression risk and transmission. It sets out the rationale and WHO recommendations for people living with HIV, including children and infants, household contacts of all ages, and clinical risk groups such as patients on dialysis or anti-TNF therapy. It also covers prisoners, health workers, migrants and other groups that may be considered case by case. The chapter ends with implementation considerations for contact investigation and a call to invest in it.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "preventive treatment",
          "heading": true
        },
        {
          "term": "tpt target",
          "heading": false
        },
        {
          "term": "household contacts",
          "heading": false
        },
        {
          "term": "tpt regimen",
          "heading": false
        },
        {
          "term": "tpt among",
          "heading": false
        },
        {
          "term": "contact investigation",
          "heading": false
        },
        {
          "term": "tpt services",
          "heading": false
        },
        {
          "term": "starting tpt",
          "heading": false
        }
      ],
      "extract": "populations for TB preventive treatment Decision point on target populations for systematic testing and TPT Which of the at-risk populations are priority targets for the programmatic scale-up of TPT, based on your country context? The WHO guidelines on TPT recommends target populations fulfilling one or more of the following criteria for PMTPT (12): • High prevalence of TB infections • High risk of progression to TB",
      "extractCut": true
    },
    {
      "id": "sec-005-chapter-3-ruling-out-tb-disease-before-tb-preven",
      "number": null,
      "title": "Chapter 3. Ruling out TB disease before TB preventive treatment",
      "level": 2,
      "pageStart": 31,
      "pageEnd": 39,
      "labelStart": "20",
      "labelEnd": "28",
      "words": 2468,
      "summary": {
        "text": "Explains how to rule out TB disease before starting preventive treatment, since treating active disease this way risks delays and drug resistance. It reviews the sensitivity of symptom screening in different groups and the added value of chest radiography, citing related WHO recommendations. It discusses algorithms combining symptoms, imaging and tests for people with HIV, contacts and other risk groups. It ends with practical steps such as expanding rapid diagnostics, specimen transport and standard operating procedures.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "ruling out",
          "heading": true
        },
        {
          "term": "chest radiography",
          "heading": false
        },
        {
          "term": "preventive treatment",
          "heading": true
        },
        {
          "term": "starting tpt",
          "heading": false
        },
        {
          "term": "chest radiographic",
          "heading": false
        },
        {
          "term": "offering tpt",
          "heading": false
        },
        {
          "term": "radiography services",
          "heading": false
        },
        {
          "term": "abnormal chest",
          "heading": false
        }
      ],
      "extract": "before TB preventive treatment Decision point on how to exclude TB disease before offering TPT How can TB disease be reliably ruled out among target populations identified for TPT? Offering TPT to someone who has TB disease can delay the resolution of disease and favour the emergence of drug resistance. Thus, excluding TB disease before initiating TPT is one of the critical steps in the preventive TB care pathway.",
      "extractCut": true
    },
    {
      "id": "sec-006-chapter-4-testing-for-tb-infection",
      "number": null,
      "title": "Chapter 4. Testing for TB infection",
      "level": 2,
      "pageStart": 39,
      "pageEnd": 47,
      "labelStart": "28",
      "labelEnd": "36",
      "words": 2496,
      "summary": {
        "text": "Discusses the role of the tuberculin skin test and interferon-gamma release assays before preventive treatment, stressing there is no gold standard for TB infection. It explains how each test works, their limitations and false negatives, and when testing need not delay treatment, such as for people with HIV and young child contacts. It covers test choice, logistics and programme considerations, and includes an algorithm flowchart for deciding on preventive treatment. It ends with a call to invest in shorter regimens.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "starting tpt",
          "heading": false
        },
        {
          "term": "tpt among",
          "heading": false
        },
        {
          "term": "tst reading",
          "heading": false
        },
        {
          "term": "unnecessary tpt",
          "heading": false
        },
        {
          "term": "igra testing",
          "heading": false
        },
        {
          "term": "infection",
          "heading": true
        },
        {
          "term": "blood specimen",
          "heading": false
        },
        {
          "term": "test reading",
          "heading": false
        }
      ],
      "extract": "infection Decision point on role of TST or IGRA What is the role of testing for TB infection before starting TPT among target populations prioritized by the ministry of health? Just as excluding TB disease is a critical step before starting TPT, confirming TB infection before starting TPT may increase the certainty that individuals targeted for TPT would benefit from it. However, there is no gold standard test to",
      "extractCut": true
    },
    {
      "id": "sec-007-chapter-5-tb-preventive-treatment",
      "number": null,
      "title": "Chapter 5. TB preventive treatment",
      "level": 2,
      "pageStart": 47,
      "pageEnd": 67,
      "labelStart": "36",
      "labelEnd": "56",
      "words": 9141,
      "summary": {
        "text": "Covers the choice among WHO-recommended TB preventive treatment regimens, from six or nine months of isoniazid to shorter rifamycin-based options such as 3HP, 3HR, 1HP and 4R. It reviews evidence on efficacy and completion rates and explains the 2020 changes to recommended durations. It also addresses dosing, regimens for contacts of drug-resistant TB, pregnancy, children and drug interactions with antiretrovirals and other medicines. The chapter closes with guidance on people who use drugs and a call to raise demand for preventive treatment.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "preventive treatment",
          "heading": true
        },
        {
          "term": "tpt regimen",
          "heading": false
        },
        {
          "term": "rifamycin-based tpt",
          "heading": false
        },
        {
          "term": "shorter tpt",
          "heading": false
        },
        {
          "term": "tpt completion",
          "heading": false
        },
        {
          "term": "tpt duration",
          "heading": false
        },
        {
          "term": "tpt options",
          "heading": false
        },
        {
          "term": "isoniazid rifapentine",
          "heading": false
        }
      ],
      "extract": "treatment Decision point on choice of TB preventive treatment Which of the WHO recommended TPT regimens should be used for different individuals in the country? TPT regimen recommendation and availability TPT broadly falls into two categories: (i) isoniazid monotherapy for six or nine months, or (ii) rifamycin- based shorter preventive treatment, on the assumption that the infecting strain is susceptible to these",
      "extractCut": true
    },
    {
      "id": "sec-008-chapter-6-safety-management-of-adverse-reactions",
      "number": null,
      "title": "Chapter 6. Safety, management of adverse reactions and other drug-related issues in TB preventive treatment",
      "level": 2,
      "pageStart": 67,
      "pageEnd": 83,
      "labelStart": "56",
      "labelEnd": "72",
      "words": 6080,
      "summary": {
        "text": "Addresses safety concerns that hinder scale-up of TB preventive treatment, including adverse drug reactions, monitoring and counselling. It tabulates known adverse events for isoniazid and rifamycins and details hepatotoxicity risks and their management. Further sections discuss interactions with other medicines, adherence, the durability of protection and fears that preventive treatment fosters drug resistance. It cites trial data finding no significant rise in rifampicin resistance and calls for patient support to ensure completion.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "adverse reactions",
          "heading": true
        },
        {
          "term": "preventive treatment",
          "heading": true
        },
        {
          "term": "receiving tpt",
          "heading": false
        },
        {
          "term": "rifamycin-based tpt",
          "heading": false
        },
        {
          "term": "during tpt",
          "heading": false
        },
        {
          "term": "tpt options",
          "heading": false
        },
        {
          "term": "hypersensitivity reactions",
          "heading": false
        },
        {
          "term": "gastrointestinal reactions",
          "heading": false
        }
      ],
      "extract": "of adverse reactions and other drug-related issues in TB preventive treatment WHO has for long recommended the use of TPT for populations at risk of TB, particularly PLHIV and child household contacts of TB patients. However programmatic scale-up of TPT has remained limited in most high TB and HIV burden countries due to other competing priorities. Concerns about the efficacy and safety of TPT and interactions with",
      "extractCut": true
    },
    {
      "id": "sec-009-chapter-7-adherence-to-tb-preventive-treatment",
      "number": null,
      "title": "Chapter 7. Adherence to TB preventive treatment",
      "level": 2,
      "pageStart": 83,
      "pageEnd": 93,
      "labelStart": "72",
      "labelEnd": "82",
      "words": 3573,
      "summary": {
        "text": "Chapter 7 of a WHO operational handbook on tuberculosis preventive treatment (TPT) addresses how national programmes can help people complete their prescribed regimen. It explains that adherence depends on many personal, social and treatment-related factors and lists person-centred measures such as confidential counselling, education in the person's language, involving families and giving clear advice on side-effects. It also covers warning people that TB disease can still develop during TPT, along with options such as reminders, digital adherence technologies, shorter regimens and community support. The chapter closes by urging investment in monitoring and in digital tools for recording and reporting TPT services.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "preventive treatment",
          "heading": true
        },
        {
          "term": "tpt regimen",
          "heading": false
        },
        {
          "term": "tpt course",
          "heading": false
        },
        {
          "term": "start tpt",
          "heading": false
        },
        {
          "term": "during tpt",
          "heading": false
        },
        {
          "term": "tpt among",
          "heading": false
        },
        {
          "term": "adherence",
          "heading": true
        },
        {
          "term": "full tpt",
          "heading": false
        }
      ],
      "extract": "preventive treatment Decision point on strategies to promote adherence to TPT What strategies should national programmes adopt to ensure adherence to the prescribed regimen by all individuals started on TPT? Adherence to treatment is a complex behaviour that is influenced by many factors such as personal motivation, beliefs about health, risks and benefits from treatment, comorbidities, competing demands that",
      "extractCut": true
    },
    {
      "id": "sec-010-chapter-8-monitoring-and-evaluation",
      "number": null,
      "title": "Chapter 8. Monitoring and evaluation",
      "level": 2,
      "pageStart": 93,
      "pageEnd": 103,
      "labelStart": "82",
      "labelEnd": "92",
      "words": 3690,
      "summary": {
        "text": "Chapter 8 of the TPT handbook sets out what data should be routinely recorded and reported, the minimum dataset for following people along the TPT cascade, and the tools for collecting it. It explains how monitoring and evaluation serve patient care, national programme management and global accountability, with examples such as counting household contacts evaluated and people completing TPT. Material on the cascade of care tracks numbers targeted, evaluated, eligible, started and completed, and explains how to estimate target populations among people living with HIV and household contacts. The chapter ends with a reminder that programmes must counsel people to make informed choices and protect them from stigma.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tpt completion",
          "heading": false
        },
        {
          "term": "initiated tpt",
          "heading": false
        },
        {
          "term": "tpt regimen",
          "heading": false
        },
        {
          "term": "completed tpt",
          "heading": false
        },
        {
          "term": "monitoring tpt",
          "heading": false
        },
        {
          "term": "prescribe tpt",
          "heading": false
        },
        {
          "term": "tpt initiation",
          "heading": false
        },
        {
          "term": "tpt out",
          "heading": false
        }
      ],
      "extract": "evaluation Decision point on minimum data for routine recording and reporting • What data should be routinely captured and reported to the national level for programme management? • What is the minimum dataset needed to monitor individual case management and monitor progress across the TPT pathway? • What tools and methods should be used to facilitate data collection and reporting? Monitoring and evaluation (M&E)",
      "extractCut": true
    },
    {
      "id": "sec-011-chapter-9-ethics-and-tb-preventive-treatment",
      "number": null,
      "title": "Chapter 9. Ethics and TB preventive treatment",
      "level": 2,
      "pageStart": 103,
      "pageEnd": 106,
      "labelStart": "92",
      "labelEnd": "95",
      "words": 1559,
      "summary": {
        "text": "Chapter 9 of the TPT handbook discusses ethical considerations in delivering preventive treatment to people who are not ill or infectious. It stresses weighing individual benefits against harms, limiting testing and treatment to groups at proven risk, and ensuring that taking TPT is a voluntary, informed choice grounded in human rights. It also addresses equity, confidentiality, stigma and the need for adequate communication resources so that individuals and communities can decide autonomously.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tpt carries",
          "heading": false
        },
        {
          "term": "tpt communication",
          "heading": false
        },
        {
          "term": "appropriate tpt",
          "heading": false
        },
        {
          "term": "preventive treatment",
          "heading": true
        },
        {
          "term": "regarding tpt",
          "heading": false
        },
        {
          "term": "informed consent",
          "heading": false
        },
        {
          "term": "human rights",
          "heading": false
        },
        {
          "term": "informed choices",
          "heading": false
        }
      ],
      "extract": "Chapter 9. Ethics and TB preventive treatment Decision on ethical issues in TPT implementation What are ethical considerations and related actions for programme management of TPT? Implementation considerations In general, only about 5–10% of people infected with M. tuberculosis will develop TB disease at some point in their lifetime. The risk of TB infection progressing to TB disease is much higher for some groups,",
      "extractCut": true
    },
    {
      "id": "sec-012-annex-1-list-of-key-messages",
      "number": null,
      "title": "Annex 1. List of key messages",
      "level": 2,
      "pageStart": 106,
      "pageEnd": 116,
      "labelStart": "95",
      "labelEnd": "105",
      "words": 5406,
      "summary": {
        "text": "Annex 1 of the TPT handbook lists key messages for ministries of health and for health care workers. Messages for ministries recall commitments made at the 2018 UN High-Level Meeting on TB and the End TB Strategy targets, and present TPT as an effective intervention that substantially lowers the risk of TB disease. Messages for health workers cover shorter rifapentine- or rifampicin-based regimens, which are reported to be easier to complete, plus counselling before treatment, ruling out TB disease and managing adverse events. Notes point to funding sources and to the Global Drug Facility for medicines.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tpt regimens",
          "heading": false
        },
        {
          "term": "rifamycin-based tpt",
          "heading": false
        },
        {
          "term": "shorter tpt",
          "heading": false
        },
        {
          "term": "stop tpt",
          "heading": false
        },
        {
          "term": "tpt saves",
          "heading": false
        },
        {
          "term": "starting tpt",
          "heading": false
        },
        {
          "term": "offered tpt",
          "heading": false
        },
        {
          "term": "receiving tpt",
          "heading": false
        }
      ],
      "extract": "Messages for the ministry of health • National governments have made a commitment at the first ever UN High Level Meeting on TB on 26th September 2018 towards “preventing tuberculosis for those most at risk of falling ill through the rapid scaling up of access to testing for tuberculosis infection, according to the domestic situation, and the provision of preventive treatment, with a focus on high-burden countries,",
      "extractCut": true
    },
    {
      "id": "sec-013-annex-2-coordination-mechanisms-to-support-pmtpt",
      "number": null,
      "title": "Annex 2. Coordination mechanisms to support PMTPT",
      "level": 2,
      "pageStart": 116,
      "pageEnd": 118,
      "labelStart": "105",
      "labelEnd": "107",
      "words": 691,
      "summary": {
        "text": "Annex 2 recommends that ministries of health set up or strengthen a joint national coordinating body and a technical expert working group to drive scale-up of programmatic TPT management. It outlines their terms of reference, membership and secretariat arrangements, and asks TB and HIV programmes to fund regular meetings.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "support pmtpt",
          "heading": true
        },
        {
          "term": "coordinating body",
          "heading": false
        },
        {
          "term": "national coordinating",
          "heading": false
        },
        {
          "term": "tpt services",
          "heading": false
        },
        {
          "term": "national scale-up",
          "heading": false
        },
        {
          "term": "national technical",
          "heading": false
        },
        {
          "term": "joint national",
          "heading": false
        },
        {
          "term": "technical working",
          "heading": false
        }
      ],
      "extract": "mechanisms to support PMTPT The ministry of health should create and strengthen a joint national coordinating body and/or national technical expert working group to support national scale-up of PMTPT through implementation of the latest global guidelines. Alternatively, the mandate of an existing body that can serve both a management and technical function may be expanded to advise the ministry of health and",
      "extractCut": true
    },
    {
      "id": "sec-014-annex-3-costing-considerations-for-programmatic",
      "number": null,
      "title": "Annex 3. Costing considerations for programmatic management of TB preventive treatment",
      "level": 2,
      "pageStart": 118,
      "pageEnd": 120,
      "labelStart": "107",
      "labelEnd": "109",
      "words": 348,
      "summary": {
        "text": "Annex 3 lists the main cost drivers to consider when budgeting for programmatic TPT management. These include target population sizes, tests for TB infection and chest radiography, human resources, medicines and procurement, and recording and reporting systems.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "preventive treatment",
          "heading": true
        },
        {
          "term": "programmatic management",
          "heading": true
        },
        {
          "term": "procurement fees",
          "heading": false
        },
        {
          "term": "chest radiography",
          "heading": false
        },
        {
          "term": "at-risk populations",
          "heading": false
        },
        {
          "term": "radiography services",
          "heading": false
        },
        {
          "term": "tpt",
          "heading": false
        },
        {
          "term": "specimen collection",
          "heading": false
        }
      ],
      "extract": "for programmatic management of TB preventive treatment When preparing a budget for PMTPT, the following considerations need to be made given that these are major cost determinants: • Estimated burden – Populations of each target group (PLHIV, contacts, clinical risk groups, other risk groups) – Number of households and other sites (health facilities, ARV centres) to be covered for expansion of TPT activities •",
      "extractCut": true
    },
    {
      "id": "sec-015-annex-4-planning-checklist-for-pmtpt",
      "number": null,
      "title": "Annex 4. Planning checklist for PMTPT",
      "level": 2,
      "pageStart": 120,
      "pageEnd": 122,
      "labelStart": "109",
      "labelEnd": "111",
      "words": 308,
      "summary": {
        "text": "Annex 4 provides a planning checklist for programmatic TPT management, with columns for current status and next steps. Activities covered include strategic planning, guideline updates, coverage of risk groups, training, advocacy, community outreach and medicine supply and stock management.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pmtpt",
          "heading": true
        },
        {
          "term": "household contacts",
          "heading": false
        },
        {
          "term": "contacts years",
          "heading": false
        },
        {
          "term": "child household",
          "heading": false
        },
        {
          "term": "tpt",
          "heading": false
        },
        {
          "term": "adverse events",
          "heading": false
        },
        {
          "term": "key stakeholders",
          "heading": false
        },
        {
          "term": "group meeting",
          "heading": false
        }
      ],
      "extract": "PMTPT Activity Current status Next Steps National TB Strategic Plan (NSP) Planning meeting of key stakeholders as a PMTPT coordinating mechanism Funding estimates to implement new guidelines National PMTPT indicators agreed NSP revision Guidelines update National technical expert group meeting Identification of (priority) risk groups Diagnostic algorithm (role of test for TB infection and chest radiography)",
      "extractCut": true
    },
    {
      "id": "sec-016-annex-5-answers-to-frequently-asked-questions-on",
      "number": null,
      "title": "Annex 5. Answers to frequently asked questions on TST",
      "level": 2,
      "pageStart": 122,
      "pageEnd": 127,
      "labelStart": "111",
      "labelEnd": "116",
      "words": 2363,
      "summary": {
        "text": "Annex 5 answers frequently asked questions about the tuberculin skin test (TST) for TB infection. It explains how the test works, the standard tuberculin doses and intradermal injection technique, and how to read and measure the induration, including the ballpoint pen method. It also covers interpreting results, causes of false-positive and false-negative readings, and the limited effect of BCG vaccination given at birth.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tst",
          "heading": true
        },
        {
          "term": "tst reactions",
          "heading": false
        },
        {
          "term": "tuberculin skin",
          "heading": false
        },
        {
          "term": "tuberculin ppd",
          "heading": false
        },
        {
          "term": "tst reversion",
          "heading": false
        },
        {
          "term": "left forearm",
          "heading": false
        },
        {
          "term": "tst administration",
          "heading": false
        },
        {
          "term": "boosted reaction",
          "heading": false
        }
      ],
      "extract": "asked questions on TST What is tuberculin skin testing (139)? Tuberculin skin test (TST), first introduced in 1908, remains the most commonly used test for TB infection in the world due to its low cost and feasibility to implement in low resource settings. There is no need for complex laboratory equipment or procedures or trained technicians, although training is required for proper intradermal administration of the",
      "extractCut": true
    },
    {
      "id": "sec-017-annex-6-answers-to-frequently-asked-questions-on",
      "number": null,
      "title": "Annex 6. Answers to frequently asked questions on IGRAs",
      "level": 2,
      "pageStart": 127,
      "pageEnd": 130,
      "labelStart": "116",
      "labelEnd": "119",
      "words": 1477,
      "summary": {
        "text": "Annex 6 answers frequently asked questions about interferon-gamma release assays (IGRAs) for TB infection, including the two commercial tests WHO reviewed in 2017. It explains that IGRAs measure interferon-gamma released by white blood cells exposed to M. tuberculosis-specific antigens absent from BCG strains, and that like TST they cannot separate infection from disease. It also covers specimen handling, interpretation and how to handle discordant or borderline results.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "igras",
          "heading": true
        },
        {
          "term": "ifn-g concentration",
          "heading": false
        },
        {
          "term": "peptides representing",
          "heading": false
        },
        {
          "term": "effector cells",
          "heading": false
        },
        {
          "term": "representing esat",
          "heading": false
        },
        {
          "term": "blood cells",
          "heading": false
        },
        {
          "term": "false-positive igra",
          "heading": false
        },
        {
          "term": "igra conversion",
          "heading": false
        }
      ],
      "extract": "Annex 6. Answers to frequently asked questions on IGRAs What are IGRAs? Interferon gamma release assays (IGRAs) are whole-blood tests that can aid in diagnosing M. tuberculosis infection (43). Like TST, IGRAs cannot differentiate between TB infection and TB disease. WHO reviewed available evidence around the two most widely used IGRAs in 2017, QuantiFERON®-TB Gold In-Tube test (QFT-GIT) and T-SPOT.TB test (T-Spot),",
      "extractCut": true
    },
    {
      "id": "sec-018-references",
      "number": null,
      "title": "References",
      "level": 2,
      "pageStart": 130,
      "pageEnd": 140,
      "labelStart": "119",
      "labelEnd": "129",
      "words": 4580,
      "summary": {
        "text": "The reference list for the TPT handbook, citing studies on latent TB burden and prognosis, contact investigation and WHO strategies and guidelines, followed by the text of a patient information leaflet on TB infection and preventive treatment.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "accessed march",
          "heading": false
        },
        {
          "term": "infect dis",
          "heading": false
        },
        {
          "term": "respir dis",
          "heading": false
        },
        {
          "term": "latent tuberculosis",
          "heading": false
        },
        {
          "term": "clin infect",
          "heading": false
        },
        {
          "term": "isoniazid preventive",
          "heading": false
        },
        {
          "term": "lung dis",
          "heading": false
        },
        {
          "term": "latent mycobacterium",
          "heading": false
        }
      ],
      "extract": "1. Houben RMGJ, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLOS Med. 2016;13(10):e1002152. 2. Cohen A, Mathiasen VD, Schön T, Wejse C. The global prevalence of latent tuberculosis: a systematic review and meta-analysis. Eur Respir J. 2019;54(3):1900655. 3. Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis infection. N",
      "extractCut": true
    }
  ],
  "checks": {
    "tocAlignment": {
      "listed_not_found": {
        "count": 0,
        "items": []
      },
      "found_not_listed": {
        "count": 3,
        "items": [
          "1 People with elevated risk of progression from infection to TB disease",
          "1 Assessment of contacts of TB patients",
          "3 Initiation (start) and completion of TPT"
        ]
      },
      "page_mismatch": {
        "count": 0,
        "items": []
      }
    },
    "figureSequenceGaps": [
      "table 5.1"
    ],
    "pageLabelConflicts": {
      "count": 0,
      "items": []
    }
  },
  "withheld": false,
  "keywords": [
    {
      "term": "tpt regimen",
      "heading": false
    },
    {
      "term": "tpt among",
      "heading": false
    },
    {
      "term": "tpt completion",
      "heading": false
    },
    {
      "term": "tpt scale-up",
      "heading": false
    },
    {
      "term": "tpt target",
      "heading": false
    },
    {
      "term": "starting tpt",
      "heading": false
    },
    {
      "term": "tpt course",
      "heading": false
    },
    {
      "term": "receiving tpt",
      "heading": false
    },
    {
      "term": "tpt services",
      "heading": true
    },
    {
      "term": "tpt options",
      "heading": false
    },
    {
      "term": "tpt out",
      "heading": true
    },
    {
      "term": "monitoring tpt",
      "heading": false
    }
  ],
  "pageLabels": [
    {
      "physical": 1,
      "label": "a",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 2,
      "label": "b",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 3,
      "label": "i",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 4,
      "label": "ii",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 5,
      "label": "iii",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 6,
      "label": "iv",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 7,
      "label": "v",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 8,
      "label": "vi",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 9,
      "label": "vii",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 10,
      "label": "viii",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 11,
      "label": "ix",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 12,
      "label": "1",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 13,
      "label": "2",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 14,
      "label": "3",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 15,
      "label": "4",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 16,
      "label": "5",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 17,
      "label": "6",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 18,
      "label": "7",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 19,
      "label": "8",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 20,
      "label": "9",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 21,
      "label": "10",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 22,
      "label": "11",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 23,
      "label": "12",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 24,
      "label": "13",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 25,
      "label": "14",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 26,
      "label": "15",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 27,
      "label": "16",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 28,
      "label": "17",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 29,
      "label": "18",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 30,
      "label": "19",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 31,
      "label": "20",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 32,
      "label": "21",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 33,
      "label": "22",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 34,
      "label": "23",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 35,
      "label": "24",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 36,
      "label": "25",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 37,
      "label": "26",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 38,
      "label": "27",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 39,
      "label": "28",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 40,
      "label": "29",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 41,
      "label": "30",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 42,
      "label": "31",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 43,
      "label": "32",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 44,
      "label": "33",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 45,
      "label": "34",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 46,
      "label": "35",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 47,
      "label": "36",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 48,
      "label": "37",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 49,
      "label": "38",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 50,
      "label": "39",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 51,
      "label": "40",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 52,
      "label": "41",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 53,
      "label": "42",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 54,
      "label": "43",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 55,
      "label": "44",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 56,
      "label": "45",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 57,
      "label": "46",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 58,
      "label": "47",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 59,
      "label": "48",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 60,
      "label": "49",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 61,
      "label": "50",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 62,
      "label": "51",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 63,
      "label": "52",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 64,
      "label": "53",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 65,
      "label": "54",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 66,
      "label": "55",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 67,
      "label": "56",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 68,
      "label": "57",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 69,
      "label": "58",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 70,
      "label": "59",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 71,
      "label": "60",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 72,
      "label": "61",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 73,
      "label": "62",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 74,
      "label": "63",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 75,
      "label": "64",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 76,
      "label": "65",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 77,
      "label": "66",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 78,
      "label": "67",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 79,
      "label": "68",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 80,
      "label": "69",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 81,
      "label": "70",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 82,
      "label": "71",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 83,
      "label": "72",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 84,
      "label": "73",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 85,
      "label": "74",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 86,
      "label": "75",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 87,
      "label": "76",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 88,
      "label": "77",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 89,
      "label": "78",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 90,
      "label": "79",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 91,
      "label": "80",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 92,
      "label": "81",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 93,
      "label": "82",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 94,
      "label": "83",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 95,
      "label": "84",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 96,
      "label": "85",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 97,
      "label": "86",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 98,
      "label": "87",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 99,
      "label": "88",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 100,
      "label": "89",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 101,
      "label": "90",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 102,
      "label": "91",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 103,
      "label": "92",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 104,
      "label": "93",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 105,
      "label": "94",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 106,
      "label": "95",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 107,
      "label": "96",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 108,
      "label": "97",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 109,
      "label": "98",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 110,
      "label": "99",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 111,
      "label": "100",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 112,
      "label": "101",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 113,
      "label": "102",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 114,
      "label": "103",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 115,
      "label": "104",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 116,
      "label": "105",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 117,
      "label": "106",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 118,
      "label": "107",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 119,
      "label": "108",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 120,
      "label": "109",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 121,
      "label": "110",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 122,
      "label": "111",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 123,
      "label": "112",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 124,
      "label": "113",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 125,
      "label": "114",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 126,
      "label": "115",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 127,
      "label": "116",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 128,
      "label": "117",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 129,
      "label": "118",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 130,
      "label": "119",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 131,
      "label": "120",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 132,
      "label": "121",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 133,
      "label": "122",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 134,
      "label": "123",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 135,
      "label": "124",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 136,
      "label": "125",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 137,
      "label": "126",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 138,
      "label": "127",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 139,
      "label": "128",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 140,
      "label": "129",
      "source": "pdf-labels",
      "confidence": 0.7
    }
  ],
  "figures": [
    {
      "kind": "figure",
      "number": "1.1",
      "title": "Cascade of TB case finding and preventive treatment",
      "page": 15,
      "pageLabel": "4",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "1.2",
      "title": "Implementation considerations in the programmatic management of TPT",
      "page": 15,
      "pageLabel": "4",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "table",
      "number": "1.1",
      "title": "Recommendations in the WHO consolidated guidelines on",
      "page": 16,
      "pageLabel": "5",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "figure",
      "number": "2.1",
      "title": "Indicative costing items to strengthen contact investigations",
      "page": 25,
      "pageLabel": "14",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "box",
      "number": "2.1",
      "title": "10 key steps in contact investigation* 1. Review available index patient information 2. Assess duration and degree of infectiousness of index TB patient to identify contacts 3. Counsel index patient and enumerate household and close contacts 4. Develop plan for contact investigation in consultation",
      "page": 29,
      "pageLabel": "18",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "3.1",
      "title": "Key steps in ruling out TB and considering TPT",
      "page": 35,
      "pageLabel": "24",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "4.1",
      "title": "Characteristic features of TST and IGRA (43)",
      "page": 42,
      "pageLabel": "31",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "5.2",
      "title": "Recommended dosages of medicines for TB preventive treatment",
      "page": 52,
      "pageLabel": "41",
      "confidence": 0.7,
      "evidence": [
        "referenced"
      ]
    },
    {
      "kind": "table",
      "number": "5.3",
      "title": "Preventive TB treatment completion",
      "page": 58,
      "pageLabel": "47",
      "confidence": 0.7,
      "evidence": [
        "referenced"
      ]
    },
    {
      "kind": "figure",
      "number": "5.1",
      "title": "Key elements for integrating TPT services into DSD models for ART",
      "page": 61,
      "pageLabel": "50",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "6.1",
      "title": "Likely adverse events with drugs used for TPT",
      "page": 68,
      "pageLabel": "57",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "6.2",
      "title": "Summary of adverse events and treatment withdrawals because of",
      "page": 70,
      "pageLabel": "59",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "6.3",
      "title": "Management of potential adverse reactions following treatment with 3HP9",
      "page": 72,
      "pageLabel": "61",
      "confidence": 0.6,
      "evidence": [
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "6.4",
      "title": "Common drug–drug interactions of isoniazid and rifamycins",
      "page": 75,
      "pageLabel": "64",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "box",
      "number": "7.1",
      "title": "Example of an adherence plan • Review the understanding of persons on TPT or caregivers about TB",
      "page": 88,
      "pageLabel": "77",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "figure",
      "number": "8.1",
      "title": "Use of health data at different levels of the health system",
      "page": 93,
      "pageLabel": "82",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "8.2",
      "title": "Critical numbers to monitor at different steps of the TPT pathway",
      "page": 94,
      "pageLabel": "83",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "box",
      "number": "8.1",
      "title": "How to calculate the number of people eligible for TPT? This is a common question facing the programme manager and is important strategic",
      "page": 95,
      "pageLabel": "84",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "box",
      "number": "8.2",
      "title": "Example of a review of medical records to assess coverage and completion of",
      "page": 99,
      "pageLabel": "88",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "box",
      "number": "8.3",
      "title": "Prevent TB: a prototype mobile application to support PMTPT and screening The Global TB Programme of WHO has developed a mobile application (app) to facilitate",
      "page": 100,
      "pageLabel": "89",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    }
  ],
  "images": [
    {
      "id": "vfig-p015",
      "file": "figures/vfig-p015.webp",
      "page": 15,
      "shows": [
        "Figure 1.1",
        "Figure 1.2"
      ],
      "narratives": {
        "en": "Two diagrams. Figure 1.1 is a flowchart from 'Target population' to 'Active TB case finding', splitting into 'Presumptive TB' (test for TB disease; if TB confirmed, provide TB treatment; if no TB, give TPT) and 'No TB' (testing for TB infection*, assess for TPT, give TPT), all ending in 'Systematic follow-up'; the footnote reads '*PLHIV and child household contacts aged < 5 years'. Figure 1.2 is a ring of six circles around 'Additional funding': national policy or guidelines, health infrastructure, human resource capacity and training, demand creation, supervision and monitoring, and review and policy adjustment.",
        "ar": "مخططان. الشكل 1.1 مخطط انسيابي يبدأ من «الفئة المستهدفة» إلى «البحث النشط عن حالات السل»، ثم يتفرع إلى «السل المفترض» (اختبار مرض السل؛ عند تأكيد السل يُقدَّم علاج السل، وعند عدم وجوده يُعطى العلاج الوقائي من السل) و«لا سل» (اختبار عدوى السل*، وتقييم الأهلية للعلاج الوقائي، وإعطاء العلاج الوقائي)، وتنتهي جميعها بـ«المتابعة المنهجية»؛ وتقول الحاشية: «*المتعايشون مع فيروس العوز المناعي البشري والمخالطون المنزليون من الأطفال دون سن 5 سنوات». والشكل 1.2 حلقة من ست دوائر حول «التمويل الإضافي»: السياسة أو المبادئ التوجيهية الوطنية، والبنية التحتية الصحية، وقدرات الموارد البشرية والتدريب، وتوليد الطلب، والإشراف والرصد، والمراجعة وتعديل السياسات.",
        "zh": "两幅图。图1.1为流程图，从“目标人群”到“主动发现结核病病例”，再分为“疑似结核病”（检测结核病；确诊结核病则提供结核病治疗，无结核病则给予结核病预防性治疗）和“无结核病”（检测结核感染*、评估结核病预防性治疗、给予结核病预防性治疗），最终均进入“系统随访”；脚注为“*艾滋病毒感染者和5岁以下儿童家庭接触者”。图1.2为围绕“额外资金”的六个圆圈组成的环：国家政策或指南、卫生基础设施、人力资源能力和培训、需求创造、督导和监测，以及审查和政策调整。",
        "es": "Dos diagramas. La figura 1.1 es un diagrama de flujo que va de «Población destinataria» a «Búsqueda activa de casos de TB» y se divide en «Presunta TB» (prueba de enfermedad tuberculosa; si se confirma la TB, se administra tratamiento antituberculoso; si no hay TB, se administra TPT) y «Sin TB» (prueba de infección tuberculosa*, evaluación para el TPT y administración del TPT), y todo termina en «Seguimiento sistemático»; la nota dice «*PVVIH y contactos domiciliarios menores de 5 años». La figura 1.2 es un anillo de seis círculos alrededor de «Financiación adicional»: política o directrices nacionales, infraestructura sanitaria, capacidad y formación de los recursos humanos, creación de demanda, supervisión y seguimiento, y examen y ajuste de las políticas.",
        "fr": "Deux schémas. La figure 1.1 est un logigramme allant de « Population cible » à « Recherche active des cas de TB », qui se divise en « TB présumée » (test de la TB maladie ; si la TB est confirmée, administration du traitement antituberculeux ; en l’absence de TB, administration du TPT) et « Pas de TB » (test de l’infection tuberculeuse*, évaluation pour le TPT, administration du TPT), le tout aboutissant au « Suivi systématique » ; la note indique « *PVVIH et contacts familiaux de moins de 5 ans ». La figure 1.2 est un anneau de six cercles autour de « Financement supplémentaire » : politique ou lignes directrices nationales, infrastructures de santé, capacités et formation des ressources humaines, création de la demande, supervision et suivi, et examen et ajustement des politiques.",
        "ru": "Две схемы. Рисунок 1.1 — блок-схема от «Целевой группы населения» к «Активному выявлению случаев ТБ», которая разделяется на «Предполагаемый ТБ» (тест на ТБ; при подтвержденном ТБ — лечение ТБ, при отсутствии ТБ — ПЛТ) и «Нет ТБ» (тестирование на ТБ-инфекцию*, оценка для ПЛТ, назначение ПЛТ), и все пути ведут к «Систематическому последующему наблюдению»; сноска: «*ЛЖВ и дети младше 5 лет из числа бытовых контактов». Рисунок 1.2 — кольцо из шести кругов вокруг «Дополнительного финансирования»: национальная политика или руководства, инфраструктура здравоохранения, кадровый потенциал и обучение, формирование спроса, кураторство и мониторинг, а также анализ и корректировка политики."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p025",
      "file": "figures/vfig-p025.webp",
      "page": 25,
      "shows": [
        "Figure 2.1"
      ],
      "narratives": {
        "en": "Diagram (Fig. 2.1) pairing five steps of contact investigation with indicative costing items: identification of contacts (health care worker time to interview the index TB patient, travel to the household or workplace); clinical evaluation (worker time for evaluation and follow-up, enabler or travel support for contacts); testing for TB disease or eligibility for TPT (travel support to the testing site, specimen collection transport); provide access to TPT (worker time for referral and follow-up on TPT/TB treatment initiation and social support); and recording and reporting (data capture tools such as the WHO Prevent TB mobile application, worker time). The render also includes the preceding key point and text on strengthening household contact investigation.",
        "ar": "مخطط (الشكل 2.1) يربط خمس خطوات لتقصي المخالطين ببنود تكاليف إرشادية: تحديد المخالطين (وقت العامل الصحي لمقابلة مريض السل الدال، والسفر إلى المنزل أو مكان العمل)؛ والتقييم السريري (وقت العامل للتقييم والمتابعة، ودعم التمكين أو السفر للمخالطين)؛ واختبار مرض السل أو الأهلية للعلاج الوقائي (دعم السفر إلى موقع الاختبار، ونقل العينات)؛ وإتاحة العلاج الوقائي من السل (وقت العامل للإحالة ومتابعة بدء العلاج الوقائي أو علاج السل وخطط الدعم الاجتماعي)؛ والتسجيل والإبلاغ (أدوات جمع البيانات مثل تطبيق WHO Prevent TB للهاتف المحمول، ووقت العامل). ويتضمن العرض أيضاً النقطة الرئيسية السابقة ونصاً عن تعزيز تقصي المخالطين المنزليين.",
        "zh": "示意图（图2.1），将接触者调查的五个步骤与指示性成本项目对应：识别接触者（卫生工作者访谈指示结核病患者的时间、前往家庭或工作场所的差旅）；临床评估（工作者进行评估和随访的时间、为接触者提供的激励或差旅支持）；检测结核病或评估结核病预防性治疗资格（前往检测点的差旅支持、标本采集运输）；提供结核病预防性治疗（工作者转诊并跟进预防性治疗/结核病治疗启动及社会支持计划的时间）；以及记录和报告（数据采集工具，如世卫组织Prevent TB手机应用程序，以及工作者时间）。该渲染图还包含前面的要点和关于加强家庭接触者调查的正文。",
        "es": "Diagrama (fig. 2.1) que asocia cinco pasos de la investigación de contactos con partidas de costos indicativas: identificación de contactos (tiempo del trabajador de salud para entrevistar al paciente índice con TB, desplazamiento al hogar o lugar de trabajo); evaluación clínica (tiempo del trabajador para la evaluación y el seguimiento, apoyo facilitador o de transporte para los contactos); pruebas de enfermedad tuberculosa o de idoneidad para el TPT (apoyo para el desplazamiento al lugar de la prueba, transporte de muestras); acceso al TPT (tiempo del trabajador para la derivación y el seguimiento del inicio del TPT o del tratamiento antituberculoso y de los planes de apoyo social); y registro y notificación (herramientas de recopilación de datos como la aplicación móvil WHO Prevent TB, tiempo del trabajador). La imagen incluye también el punto clave anterior y el texto sobre el fortalecimiento de la investigación de contactos domiciliarios.",
        "fr": "Schéma (fig. 2.1) associant cinq étapes de l’investigation des contacts à des postes de coûts indicatifs : identification des contacts (temps de l’agent de santé pour interroger le patient index atteint de TB, déplacement au domicile ou sur le lieu de travail) ; évaluation clinique (temps de l’agent pour l’évaluation et le suivi, aide incitative ou au transport pour les contacts) ; dépistage de la TB maladie ou de l’éligibilité au TPT (aide au déplacement vers le site de dépistage, transport des échantillons) ; accès au TPT (temps de l’agent pour l’orientation et le suivi de l’instauration du TPT ou du traitement antituberculeux et des dispositifs de soutien social) ; et enregistrement et notification (outils de saisie des données comme l’application mobile WHO Prevent TB, temps de l’agent). Le rendu inclut aussi le point clé précédent et le texte sur le renforcement de l’investigation des contacts familiaux.",
        "ru": "Схема (рис. 2.1), сопоставляющая пять этапов обследования контактов с ориентировочными статьями расходов: выявление контактов (время медработника на опрос индексного пациента с ТБ, поездки по месту жительства или работы); клиническая оценка (время медработника на оценку и наблюдение, стимулирующая или транспортная поддержка контактов); тестирование на ТБ или пригодность к ПЛТ (транспортная поддержка для посещения пункта тестирования, транспортировка образцов); обеспечение доступа к ПЛТ (время медработника на направление и контроль начала ПЛТ/лечения ТБ и программы социальной поддержки); регистрация и отчетность (инструменты сбора данных, например мобильное приложение ВОЗ Prevent TB, время медработника). Изображение также включает предшествующий ключевой момент и текст об усилении обследования бытовых контактов."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p026",
      "file": "figures/vfig-p026.webp",
      "page": 26,
      "shows": [
        "Figure 2.2"
      ],
      "narratives": {
        "en": "Diagram (Fig. 2.2) of six columns of blue boxes listing building blocks for contact investigation: prioritize contact investigation, define roles and responsibility, provide standard protocols and procedures, guidance on recording and reporting; health care worker, community workers/volunteers, former TB patients; counselling about the importance of contact investigation, risk assessment, TPT and adverse events management, interview techniques, follow-up and basic data collection; support for home visits/travel to health facility, additional human resources, enablers and incentives, information and communication tools; conduct early interview (one week), use local language, include environment assessment, include family counselling, referral for testing and starting TPT; and provide disclosure counselling (family/contact), ensure respectful treatment, obtain consent for investigation. Column headings are not shown in this render.",
        "ar": "مخطط (الشكل 2.2) من ستة أعمدة من المربعات الزرقاء تسرد اللبنات الأساسية لتقصي المخالطين: إعطاء الأولوية لتقصي المخالطين، وتحديد الأدوار والمسؤوليات، وتوفير بروتوكولات وإجراءات موحدة، وإرشادات بشأن التسجيل والإبلاغ؛ والعامل الصحي، والعاملون المجتمعيون/المتطوعون، ومرضى السل السابقون؛ والمشورة بشأن أهمية تقصي المخالطين، وتقييم المخاطر والعلاج الوقائي من السل وإدارة الأحداث الضائرة، وتقنيات المقابلة، والمتابعة وجمع البيانات الأساسية؛ ودعم الزيارات المنزلية/السفر إلى المرفق الصحي، والموارد البشرية الإضافية، والعوامل التمكينية والحوافز، وأدوات المعلومات والاتصال؛ وإجراء مقابلة مبكرة (أسبوع واحد)، واستخدام اللغة المحلية، وإدراج تقييم البيئة، وإدراج مشورة الأسرة، والإحالة للاختبار وبدء العلاج الوقائي؛ وتقديم المشورة بشأن الإفصاح (الأسرة/المخالط)، وضمان المعاملة باحترام، والحصول على الموافقة على التقصي. ولا تظهر عناوين الأعمدة في هذا العرض.",
        "zh": "示意图（图2.2），由六列蓝色方框组成，列出加强接触者调查的基本要素：优先开展接触者调查、明确角色和职责、提供标准规程和程序、记录和报告指导；卫生工作者、社区工作者/志愿者、既往结核病患者；关于接触者调查重要性的咨询、风险评估、结核病预防性治疗和不良事件管理、访谈技巧、随访和基本数据收集；家访/前往卫生机构的支持、额外人力资源、激励措施、信息和交流工具；尽早访谈（一周内）、使用当地语言、包括环境评估、包括家庭咨询、转诊检测并启动结核病预防性治疗；以及提供披露咨询（家庭/接触者）、确保尊重对待、获得调查同意。本渲染图中未显示列标题。",
        "es": "Diagrama (fig. 2.2) de seis columnas de recuadros azules que enumeran los elementos básicos de la investigación de contactos: priorizar la investigación de contactos, definir funciones y responsabilidades, proporcionar protocolos y procedimientos normalizados, orientación sobre registro y notificación; trabajador de salud, trabajadores comunitarios/voluntarios, antiguos pacientes con TB; asesoramiento sobre la importancia de la investigación de contactos, evaluación del riesgo, TPT y manejo de eventos adversos, técnicas de entrevista, seguimiento y recopilación básica de datos; apoyo para visitas domiciliarias/desplazamiento al establecimiento de salud, recursos humanos adicionales, facilitadores e incentivos, herramientas de información y comunicación; realizar una entrevista temprana (una semana), usar el idioma local, incluir una evaluación del entorno, incluir asesoramiento familiar, derivación para pruebas e inicio del TPT; y proporcionar asesoramiento sobre la revelación (familia/contacto), garantizar un trato respetuoso, obtener el consentimiento para la investigación. Los encabezados de columna no aparecen en esta imagen.",
        "fr": "Schéma (fig. 2.2) de six colonnes de cases bleues énumérant les éléments constitutifs de l’investigation des contacts : donner la priorité à l’investigation des contacts, définir les rôles et responsabilités, fournir des protocoles et procédures normalisés, orientations sur l’enregistrement et la notification ; agent de santé, agents communautaires/bénévoles, anciens patients atteints de TB ; conseil sur l’importance de l’investigation des contacts, évaluation des risques, TPT et prise en charge des événements indésirables, techniques d’entretien, suivi et collecte de données de base ; soutien aux visites à domicile/déplacements vers l’établissement de santé, ressources humaines supplémentaires, mesures incitatives, outils d’information et de communication ; mener un entretien précoce (une semaine), utiliser la langue locale, inclure une évaluation de l’environnement, inclure un conseil familial, orientation pour le dépistage et le démarrage du TPT ; et fournir un conseil sur la divulgation (famille/contact), garantir un traitement respectueux, obtenir le consentement à l’investigation. Les intitulés des colonnes n’apparaissent pas dans ce rendu.",
        "ru": "Схема (рис. 2.2) из шести столбцов синих блоков с основными элементами обследования контактов: приоритизация обследования контактов, определение ролей и обязанностей, стандартные протоколы и процедуры, руководство по регистрации и отчетности; медицинский работник, общественные работники/волонтеры, бывшие пациенты с ТБ; консультирование о важности обследования контактов, оценка риска, ПЛТ и ведение нежелательных явлений, методы интервьюирования, последующее наблюдение и сбор базовых данных; поддержка визитов на дом/поездок в медучреждение, дополнительные кадровые ресурсы, стимулы и поощрения, информационно-коммуникационные инструменты; раннее интервью (в течение недели), использование местного языка, оценка окружающей среды, консультирование семьи, направление на тестирование и начало ПЛТ; консультирование по вопросам раскрытия информации (семья/контакт), уважительное отношение, получение согласия на обследование. Заголовки столбцов на этом изображении не показаны."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p044",
      "file": "figures/vfig-p044.webp",
      "page": 44,
      "shows": [
        "Figure 4.1"
      ],
      "narratives": {
        "en": "Flowchart (Fig. 4.1) of the algorithm for TB screening and TPT with three entry groups. People who are HIV positive are asked about any symptom of current cough, fever, weight loss or night sweats; household contacts are asked if symptomatic, and those without symptoms are split into under 5 years and 5 years and over; other risk groups go to TST or IGRA, where a positive or unavailable result leads to chest radiography and a negative result ends the pathway. Symptoms or an abnormal chest radiograph lead to 'Investigate for active TB'; people with no active TB, a normal or unavailable radiograph, or no symptoms are assessed for 'Preventive treatment contraindicated?', ending in 'Defer preventive treatment' or 'Give preventive treatment', followed by 'Follow up for active TB as necessary, even for patients who have completed preventive treatment'.",
        "ar": "مخطط انسيابي (الشكل 4.1) لخوارزمية فحص السل والعلاج الوقائي منه، بثلاث فئات للدخول. يُسأل المصابون بفيروس العوز المناعي البشري عن أي عرض من أعراض السعال الحالي أو الحمى أو فقدان الوزن أو التعرق الليلي؛ ويُسأل المخالطون المنزليون عما إذا كانت لديهم أعراض، ويُقسَّم من لا أعراض لديهم إلى من هم دون 5 سنوات ومن هم في سن 5 سنوات فأكثر؛ وتتجه فئات الخطر الأخرى إلى اختبار التوبركولين الجلدي أو مقايسة إطلاق الإنترفيرون غاما، حيث تؤدي النتيجة الإيجابية أو غير المتاحة إلى التصوير الشعاعي للصدر، وتُنهي النتيجة السلبية المسار. وتؤدي الأعراض أو الصورة الشعاعية غير الطبيعية إلى «التحري عن السل النشط»؛ ويُقيَّم من ليس لديهم سل نشط أو صورة شعاعية طبيعية أو غير متاحة أو أعراض بسؤال «هل العلاج الوقائي مضاد استطباب؟»، وينتهي ذلك بـ«تأجيل العلاج الوقائي» أو «إعطاء العلاج الوقائي»، تليه «متابعة السل النشط حسب الضرورة، حتى للمرضى الذين أكملوا العلاج الوقائي».",
        "zh": "流程图（图4.1），展示结核病筛查和结核病预防性治疗算法，有三类入口人群。艾滋病毒阳性者询问是否有当前咳嗽、发热、体重减轻或盗汗中的任一症状；家庭接触者询问是否有症状，无症状者分为5岁以下和5岁及以上；其他风险人群进行结核菌素皮肤试验或γ干扰素释放试验，结果阳性或无法获得者进行胸部X线检查，结果阴性者路径结束。有症状或胸片异常者进入“调查活动性结核病”；无活动性结核病、胸片正常或无法获得、或无症状者评估“是否存在预防性治疗禁忌症？”，结果为“推迟预防性治疗”或“给予预防性治疗”，随后“必要时随访活动性结核病，即使对已完成预防性治疗的患者也是如此”。",
        "es": "Diagrama de flujo (fig. 4.1) del algoritmo de cribado de la TB y TPT con tres grupos de entrada. A las personas con VIH se les pregunta por cualquier síntoma de tos actual, fiebre, pérdida de peso o sudores nocturnos; a los contactos domiciliarios se les pregunta si tienen síntomas, y los asintomáticos se dividen en menores de 5 años y de 5 años o más; los demás grupos de riesgo pasan a PT o IGRA, donde un resultado positivo o no disponible lleva a la radiografía de tórax y un resultado negativo pone fin al proceso. Los síntomas o una radiografía anormal llevan a «Investigar TB activa»; a las personas sin TB activa, con radiografía normal o no disponible o sin síntomas se les evalúa «¿Está contraindicado el tratamiento preventivo?», con el resultado «Aplazar el tratamiento preventivo» o «Administrar tratamiento preventivo», seguido de «Seguimiento de la TB activa según sea necesario, incluso en pacientes que han completado el tratamiento preventivo».",
        "fr": "Logigramme (fig. 4.1) de l’algorithme de dépistage de la TB et de TPT comportant trois groupes d’entrée. Les personnes vivant avec le VIH sont interrogées sur tout symptôme de toux actuelle, fièvre, perte de poids ou sueurs nocturnes ; on demande aux contacts familiaux s’ils présentent des symptômes, et les personnes asymptomatiques sont réparties entre moins de 5 ans et 5 ans et plus ; les autres groupes à risque passent un TCT ou un IGRA, un résultat positif ou indisponible menant à la radiographie thoracique et un résultat négatif mettant fin au parcours. Des symptômes ou une radiographie anormale mènent à « Rechercher une TB active » ; les personnes sans TB active, avec une radiographie normale ou indisponible ou sans symptômes sont évaluées sur la question « Traitement préventif contre-indiqué ? », aboutissant à « Différer le traitement préventif » ou « Administrer le traitement préventif », puis à « Suivi de la TB active si nécessaire, même pour les patients ayant achevé le traitement préventif ».",
        "ru": "Блок-схема (рис. 4.1) алгоритма скрининга на ТБ и ПЛТ с тремя входными группами. Людей с ВИЧ спрашивают о любом из симптомов: текущий кашель, лихорадка, потеря веса или ночная потливость; бытовые контакты спрашивают о наличии симптомов, а бессимптомных делят на детей младше 5 лет и лиц 5 лет и старше; другие группы риска проходят ТКП или IGRA, при положительном или недоступном результате выполняется рентгенография грудной клетки, при отрицательном путь завершается. Симптомы или патологическая рентгенограмма ведут к «Обследованию на активный ТБ»; лиц без активного ТБ, с нормальной или недоступной рентгенограммой либо без симптомов оценивают по вопросу «Противопоказано ли профилактическое лечение?», что приводит к «Отложить профилактическое лечение» или «Назначить профилактическое лечение», а затем к «Наблюдению на предмет активного ТБ по мере необходимости, даже у пациентов, завершивших профилактическое лечение»."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p093",
      "file": "figures/vfig-p093.webp",
      "page": 93,
      "shows": [
        "Figure 8.1"
      ],
      "narratives": {
        "en": "Pyramid diagram (Fig. 8.1) of the use of health data at different levels of the health system. From base to apex: person-centred patient care/management, including patient monitoring; routine cascade data reviews for programme improvement, from national to facility level, including aggregate and individual-level/case surveillance data; national strategic plans and accountability towards multi-year goals and targets; and accountability towards global/UN commitments, Sustainable Development Goals. Side labels on the left are cut off in this render.",
        "ar": "مخطط هرمي (الشكل 8.1) لاستخدام البيانات الصحية على مختلف مستويات النظام الصحي. من القاعدة إلى القمة: رعاية المرضى وتدبيرهم المتمحوران حول الشخص، بما في ذلك رصد المرضى؛ والمراجعات الروتينية لبيانات السلسلة المتتالية لتحسين البرامج، من المستوى الوطني إلى مستوى المرافق، بما في ذلك البيانات الإجمالية وبيانات الترصد على المستوى الفردي/على مستوى الحالات؛ والخطط الاستراتيجية الوطنية والمساءلة تجاه الأهداف والغايات المتعددة السنوات؛ والمساءلة تجاه الالتزامات العالمية/التزامات الأمم المتحدة وأهداف التنمية المستدامة. والتسميات الجانبية على اليسار مقتطعة في هذا العرض.",
        "zh": "金字塔图（图8.1），展示卫生系统不同层级对卫生数据的使用。从底部到顶部依次为：以人为本的患者照护/管理，包括患者监测；为改进规划而进行的常规级联数据审查，从国家级到机构级，包括汇总数据和个体层面/病例监测数据；国家战略计划以及对多年度目标和指标的问责；对全球/联合国承诺和可持续发展目标的问责。本渲染图中左侧标签被截断。",
        "es": "Diagrama piramidal (fig. 8.1) del uso de los datos de salud en los distintos niveles del sistema de salud. De la base al vértice: atención/gestión de pacientes centrada en la persona, incluido el seguimiento de los pacientes; exámenes rutinarios de los datos de la cascada para mejorar el programa, del nivel nacional al de establecimiento, incluidos datos agregados y de vigilancia individual o de casos; planes estratégicos nacionales y rendición de cuentas respecto de metas y objetivos plurianuales; y rendición de cuentas respecto de los compromisos mundiales y de las Naciones Unidas y los Objetivos de Desarrollo Sostenible. Las etiquetas laterales de la izquierda aparecen cortadas en esta imagen.",
        "fr": "Diagramme pyramidal (fig. 8.1) de l’utilisation des données de santé aux différents niveaux du système de santé. De la base au sommet : soins/prise en charge centrés sur la personne, y compris le suivi des patients ; examens systématiques des données de la cascade pour améliorer le programme, du niveau national à celui des établissements, y compris les données agrégées et les données de surveillance individuelles/par cas ; plans stratégiques nationaux et redevabilité à l’égard des buts et cibles pluriannuels ; et redevabilité à l’égard des engagements mondiaux/des Nations Unies et des objectifs de développement durable. Les libellés latéraux de gauche sont tronqués dans ce rendu.",
        "ru": "Пирамидальная схема (рис. 8.1) использования медицинских данных на разных уровнях системы здравоохранения. От основания к вершине: пациентоориентированная помощь/ведение пациентов, включая мониторинг пациентов; регулярный анализ данных каскада для совершенствования программы — от национального уровня до уровня учреждений, включая агрегированные данные и данные индивидуального/поименного эпиднадзора; национальные стратегические планы и подотчетность в отношении многолетних целей и задач; подотчетность в отношении глобальных обязательств/обязательств ООН и Целей в области устойчивого развития. Боковые подписи слева на этом изображении обрезаны."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p094",
      "file": "figures/vfig-p094.webp",
      "page": 94,
      "shows": [
        "Figure 8.2"
      ],
      "narratives": {
        "en": "Arrow diagram (Fig. 8.2) of critical numbers to monitor along the TPT pathway, in five boxes from left to right: # target population, # evaluated for eligibility, # eligible for TPT*, # started TPT and # completed TPT.",
        "ar": "مخطط سهمي (الشكل 8.2) للأعداد الحاسمة التي ينبغي رصدها على طول مسار العلاج الوقائي من السل، في خمسة مربعات من اليسار إلى اليمين: عدد الفئة المستهدفة، وعدد من قُيّمت أهليتهم، وعدد المؤهلين للعلاج الوقائي*، وعدد من بدأوا العلاج الوقائي، وعدد من أكملوه.",
        "zh": "箭头图（图8.2），显示结核病预防性治疗路径中需要监测的关键数字，从左至右共五个方框：目标人群数、接受资格评估人数、符合结核病预防性治疗条件人数*、开始结核病预防性治疗人数和完成结核病预防性治疗人数。",
        "es": "Diagrama de flecha (fig. 8.2) de las cifras clave que deben vigilarse a lo largo de la vía del TPT, en cinco recuadros de izquierda a derecha: n.º de la población destinataria, n.º evaluados para determinar la idoneidad, n.º idóneos para el TPT*, n.º que iniciaron el TPT y n.º que completaron el TPT.",
        "fr": "Schéma en flèche (fig. 8.2) des chiffres essentiels à suivre le long du parcours du TPT, dans cinq cases de gauche à droite : nb de la population cible, nb évalués pour l’éligibilité, nb éligibles au TPT*, nb ayant commencé le TPT et nb ayant achevé le TPT.",
        "ru": "Схема в виде стрелки (рис. 8.2) с ключевыми показателями для мониторинга на пути ПЛТ, в пяти блоках слева направо: число лиц целевой группы, число прошедших оценку пригодности, число пригодных к ПЛТ*, число начавших ПЛТ и число завершивших ПЛТ."
      },
      "state": "draft"
    },
    {
      "id": "img-p110-1",
      "file": "images/img-p110-1.webp",
      "page": 110,
      "narratives": {
        "en": "Illustration from the patient leaflet on TB preventive treatment showing a group of six people of different ages, including a woman in a blue sari, a man in an orange robe, a woman in a blue headscarf, a young man, a girl and a small boy.",
        "ar": "رسم توضيحي من نشرة المرضى بشأن العلاج الوقائي من السل يُظهر مجموعة من ستة أشخاص من أعمار مختلفة، منهم امرأة ترتدي ساري أزرق، ورجل يرتدي رداءً برتقالياً، وامرأة ترتدي حجاباً أزرق، وشاب، وفتاة، وصبي صغير.",
        "zh": "结核病预防性治疗患者宣传单中的插图，展示了六位不同年龄的人，包括一位身穿蓝色纱丽的女性、一位身着橙色长袍的男性、一位戴蓝色头巾的女性、一位年轻男子、一个女孩和一个小男孩。",
        "es": "Ilustración del folleto para pacientes sobre el tratamiento preventivo de la TB que muestra un grupo de seis personas de distintas edades, entre ellas una mujer con un sari azul, un hombre con una túnica naranja, una mujer con un pañuelo azul en la cabeza, un hombre joven, una niña y un niño pequeño.",
        "fr": "Illustration de la brochure destinée aux patients sur le traitement préventif de la TB montrant un groupe de six personnes d’âges différents, dont une femme en sari bleu, un homme en robe orange, une femme portant un foulard bleu, un jeune homme, une fille et un petit garçon.",
        "ru": "Иллюстрация из памятки для пациентов о профилактическом лечении ТБ: группа из шести человек разного возраста, в том числе женщина в синем сари, мужчина в оранжевом одеянии, женщина в синем платке, молодой человек, девочка и маленький мальчик."
      },
      "state": "draft"
    },
    {
      "id": "img-p110-4",
      "file": "images/img-p110-4.webp",
      "page": 110,
      "narratives": {
        "en": "Diagram of three person icons, each above an empty box with a pink arrow that runs downward and branches to the right; the size of the side branch decreases from left to right while the downward arrow widens. No text labels are visible in the image.",
        "ar": "مخطط يضم ثلاث أيقونات لأشخاص، يعلو كل منها مربعاً فارغاً يخرج منه سهم وردي يتجه إلى الأسفل ويتفرع إلى اليمين؛ ويتناقص حجم الفرع الجانبي من اليسار إلى اليمين بينما يزداد عرض السهم المتجه إلى الأسفل. ولا تظهر في الصورة أي تسميات نصية.",
        "zh": "示意图，包含三个人形图标，每个图标下方有一个空白方框，方框下伸出一支粉色箭头，向下延伸并向右分支；从左到右，侧向分支逐渐变小，而向下的箭头逐渐变宽。图像中没有可见的文字标签。",
        "es": "Diagrama de tres iconos de personas, cada uno sobre un recuadro vacío del que sale una flecha rosa que desciende y se ramifica hacia la derecha; el tamaño de la rama lateral disminuye de izquierda a derecha mientras que la flecha descendente se ensancha. No se ven etiquetas de texto en la imagen.",
        "fr": "Schéma de trois icônes de personnes, chacune au-dessus d’un cadre vide d’où part une flèche rose descendante qui se ramifie vers la droite ; la taille de la branche latérale diminue de gauche à droite tandis que la flèche descendante s’élargit. Aucun libellé n’est visible dans l’image.",
        "ru": "Схема из трех значков людей, под каждым из которых пустая рамка с розовой стрелкой, идущей вниз и ответвляющейся вправо; размер бокового ответвления уменьшается слева направо, а нисходящая стрелка расширяется. Текстовых подписей на изображении нет."
      },
      "state": "draft"
    },
    {
      "id": "img-p110-5",
      "file": "images/img-p110-5.webp",
      "page": 110,
      "narratives": {
        "en": "Illustration of a young woman in profile exhaling a cloud of small particles against a dark circular background, from the patient leaflet on TB preventive treatment.",
        "ar": "رسم توضيحي لامرأة شابة في وضع جانبي تزفر سحابة من الجسيمات الصغيرة على خلفية دائرية داكنة، من نشرة المرضى بشأن العلاج الوقائي من السل.",
        "zh": "插图：一名年轻女性侧身呼出一团微小颗粒，背景为深色圆形，出自结核病预防性治疗患者宣传单。",
        "es": "Ilustración de una mujer joven de perfil que exhala una nube de pequeñas partículas sobre un fondo circular oscuro, del folleto para pacientes sobre el tratamiento preventivo de la TB.",
        "fr": "Illustration d’une jeune femme de profil exhalant un nuage de fines particules sur un fond circulaire sombre, tirée de la brochure destinée aux patients sur le traitement préventif de la TB.",
        "ru": "Иллюстрация: молодая женщина в профиль выдыхает облако мелких частиц на темном круглом фоне; из памятки для пациентов о профилактическом лечении ТБ."
      },
      "state": "draft"
    },
    {
      "id": "img-p111-1",
      "file": "images/img-p111-1.webp",
      "page": 111,
      "narratives": {
        "en": "Illustration of a health care worker in a white coat with a stethoscope, holding a clipboard, from the patient leaflet.",
        "ar": "رسم توضيحي لعاملة صحية ترتدي معطفاً أبيض وسماعة طبية وتحمل لوح كتابة، من نشرة المرضى.",
        "zh": "插图：一名身穿白大褂、佩戴听诊器、手持写字板的卫生工作者，出自患者宣传单。",
        "es": "Ilustración de una trabajadora de la salud con bata blanca y estetoscopio que sostiene una tablilla con sujetapapeles, del folleto para pacientes.",
        "fr": "Illustration d’une agente de santé en blouse blanche avec un stéthoscope, tenant un porte-bloc, tirée de la brochure destinée aux patients.",
        "ru": "Иллюстрация из памятки для пациентов: медицинский работник в белом халате со стетоскопом держит планшет с бумагами."
      },
      "state": "draft"
    },
    {
      "id": "img-p112-1",
      "file": "images/img-p112-1.webp",
      "page": 112,
      "narratives": {
        "en": "Illustration of a person placing a pill in his mouth, from the patient leaflet.",
        "ar": "رسم توضيحي لشخص يضع قرصاً دوائياً في فمه، من نشرة المرضى.",
        "zh": "插图：一个人正把药片放入口中，出自患者宣传单。",
        "es": "Ilustración de una persona que se lleva una pastilla a la boca, del folleto para pacientes.",
        "fr": "Illustration d’une personne qui porte un comprimé à sa bouche, tirée de la brochure destinée aux patients.",
        "ru": "Иллюстрация из памятки для пациентов: человек кладет таблетку в рот."
      },
      "state": "draft"
    },
    {
      "id": "img-p112-2",
      "file": "images/img-p112-2.webp",
      "page": 112,
      "narratives": {
        "en": "Red ribbon, the symbol of HIV awareness, from the patient leaflet.",
        "ar": "الشريط الأحمر، رمز التوعية بفيروس العوز المناعي البشري، من نشرة المرضى.",
        "zh": "红丝带，即艾滋病毒防治宣传标志，出自患者宣传单。",
        "es": "Lazo rojo, símbolo de la concienciación sobre el VIH, del folleto para pacientes.",
        "fr": "Ruban rouge, symbole de la sensibilisation au VIH, tiré de la brochure destinée aux patients.",
        "ru": "Красная лента — символ информирования о ВИЧ; из памятки для пациентов."
      },
      "state": "draft"
    },
    {
      "id": "img-p112-3",
      "file": "images/img-p112-3.webp",
      "page": 112,
      "narratives": {
        "en": "Illustration of a woman in a yellow headscarf with a finger on her chin, looking thoughtful, from the patient leaflet.",
        "ar": "رسم توضيحي لامرأة ترتدي حجاباً أصفر وتضع إصبعها على ذقنها في وضع تفكير، من نشرة المرضى.",
        "zh": "插图：一名戴黄色头巾的女性手指托着下巴，若有所思，出自患者宣传单。",
        "es": "Ilustración de una mujer con pañuelo amarillo en la cabeza y un dedo en la barbilla, con gesto pensativo, del folleto para pacientes.",
        "fr": "Illustration d’une femme portant un foulard jaune, un doigt sur le menton, l’air pensif, tirée de la brochure destinée aux patients.",
        "ru": "Иллюстрация из памятки для пациентов: задумчивая женщина в желтом платке, приложившая палец к подбородку."
      },
      "state": "draft"
    },
    {
      "id": "img-p113-1",
      "file": "images/img-p113-1.webp",
      "page": 113,
      "narratives": {
        "en": "Illustration of a pregnant woman holding her abdomen, from the patient leaflet.",
        "ar": "رسم توضيحي لامرأة حامل تضع يديها على بطنها، من نشرة المرضى.",
        "zh": "插图：一名孕妇双手抚着腹部，出自患者宣传单。",
        "es": "Ilustración de una mujer embarazada que se sostiene el abdomen, del folleto para pacientes.",
        "fr": "Illustration d’une femme enceinte tenant son ventre, tirée de la brochure destinée aux patients.",
        "ru": "Иллюстрация из памятки для пациентов: беременная женщина, держащая руки на животе."
      },
      "state": "draft"
    },
    {
      "id": "img-p140-1",
      "file": "images/img-p140-1.webp",
      "page": 140,
      "narratives": {
        "en": "ISBN barcode for 9789240002906.",
        "ar": "الرمز الشريطي للرقم الدولي المعياري للكتاب (ISBN) 9789240002906.",
        "zh": "国际标准书号（ISBN）条形码9789240002906。",
        "es": "Código de barras del ISBN 9789240002906.",
        "fr": "Code-barres ISBN 9789240002906.",
        "ru": "Штрихкод ISBN 9789240002906."
      },
      "state": "draft"
    }
  ],
  "tables": [
    {
      "label": "Table 1.1",
      "caption": "Table 1.1: Recommendations in the WHO consolidated guidelines on tuberculosis: tuberculosis preventive treatment¹",
      "pages": [
        16,
        17
      ],
      "columns": [
        {
          "titles": ""
        }
      ],
      "rows": [
        [
          "1.1. Identifying populations for LTBI testing and TB preventive treatment"
        ],
        [
          "People living with HIV"
        ],
        [
          "1. Adults and adolescents living with HIV who are unlikely to have active TB should receive TB preventive treatment as part of a comprehensive package of HIV care. Treatment should also be given to those on antiretroviral treatment, to pregnant women and to those who have previously been treated for TB, irrespective of the degree of immunosuppression and even if LTBI testing is unavailable."
        ],
        [
          "2. Infants aged < 12 months living with HIV who are in contact with a person with TB and who are unlikely to have active TB on an appropriate clinical evaluation or according to national guidelines should receive TB preventive treatment."
        ],
        [
          "3. Children aged ≥ 12 months living with HIV who are considered unlikely to have active TB on an appropriate clinical evaluation or according to national guidelines should be offered TB preventive treatment as part of a comprehensive package of HIV prevention and care if they live in a setting with high TB transmission, regardless of contact with TB."
        ],
        [
          "4. All children living with HIV who have successfully completed treatment for TB disease may receive TB preventive treatment."
        ],
        [
          "Household contacts (regardless of HIV status)"
        ],
        [
          "5. Children aged < 5 years who are household contacts of people with bacteriologically confirmed pulmonary TB and who are found not to have active TB on an appropriate clinical evaluation or according to national guidelines should be given TB preventive treatment even if LTBI testing is unavailable."
        ],
        [
          "6. Children aged ≥ 5 years, adolescents and adults who are household contacts of people with bacteriologically confirmed pulmonary TB who are found not to have active TB by an appropriate clinical evaluation or according to national guidelines may be given TB preventive treatment."
        ],
        [
          "7. In selected high-risk household contacts of patients with multidrug-resistant tuberculosis, preventive treatment may be considered based on individualized risk assessment and a sound clinical justification."
        ],
        [
          "Other people at risk"
        ],
        [
          "8. People who are initiating anti-TNF treatment, or receiving dialysis, or preparing for an organ or haematological transplant, or who have silicosis should be systematically tested and treated for LTBI."
        ],
        [
          "9. Systematic LTBI testing and treatment may be considered for prisoners, health workers, immigrants from countries with a high TB burden, homeless people and people who use drugs."
        ],
        [
          "10. Systematic LTBI testing and treatment is not recommended for people with diabetes, people who engage in the harmful use of alcohol, tobacco smokers and underweight people unless they also belong to other risk groups included in the above recommendations."
        ],
        [
          "1.2. Algorithms to rule out active TB disease"
        ],
        [
          "11. Adults and adolescents living with HIV should be screened for TB according to a clinical algorithm. Those who do not report any of the symptoms of current cough, fever, weight loss or night sweats are unlikely to have active TB and should be offered preventive treatment, regardless of their ART status."
        ],
        [
          "12. Adults and adolescents living with HIV who are screened for TB according to a clinical algorithm and who report any of the symptoms of current cough, fever, weight loss or night sweats may have active TB and should be evaluated for TB and other diseases and offered preventive treatment if active TB is excluded."
        ],
        [
          "13. Chest radiography may be offered to people living with HIV on ART and preventive treatment given to those with no abnormal radiographic findings."
        ],
        [
          "14. Infants and children living with HIV who have poor weight gain, fever or current cough or who have a history of contact with a person with TB should be evaluated for TB and other diseases that cause such symptoms. If TB disease is excluded after an appropriate clinical evaluation or according to national guidelines, these children should be offered TB preventive treatment, regardless of their age."
        ],
        [
          "15. The absence of any symptoms of TB and the absence of abnormal chest radiographic findings may be used to rule out active TB disease among HIV-negative household contacts aged ≥ 5 years and other risk groups before preventive treatment."
        ],
        [
          "1.3. Testing for LTBI"
        ],
        [
          "16. Either a tuberculin skin test (TST) or interferon-gamma release assay (IGRA) can be used to test for LTBI."
        ],
        [
          "1.4. TB preventive treatment options"
        ],
        [
          "17. The following options are recommended for the treatment of LTBI regardless of HIV status: 6 or 9 months of daily isoniazid, or a 3-month regimen of weekly rifapentine plus isoniazid, or a 3 month regimen of daily isoniazid plus rifampicin. A 1-month regimen of daily rifapentine plus isoniazid or 4 months of daily rifampicin alone may also be offered as alternatives."
        ],
        [
          "18. In settings with high TB transmission, adults and adolescents living with HIV who have an unknown or a positive LTBI test and are unlikely to have active TB disease should receive at least 36 months of daily isoniazid preventive therapy (IPT). Daily IPT for 36 months should be given whether or not the person is on ART, and irrespective of the degree of immunosuppression, history of previous TB treatment and pregnancy in settings considered to have a high TB transmission as defined by national authorities."
        ]
      ],
      "notes": "¹ The conditions under which these recommendations apply and more details on their implementation are discussed in the following chapters. [Transcriber: single-column table; rows include section headings (1.1–1.4) and population subheadings as printed.]",
      "narratives": {
        "en": "The table lists the 18 recommendations of the WHO consolidated guidelines on tuberculosis preventive treatment. They are grouped under identifying populations for LTBI testing and TB preventive treatment (people living with HIV, household contacts, other people at risk), algorithms to rule out active TB disease, testing for LTBI, and TB preventive treatment options.",
        "ar": "يسرد الجدول التوصيات الثماني عشرة الواردة في المبادئ التوجيهية الموحدة للمنظمة بشأن العلاج الوقائي من السل. وهي مصنفة تحت تحديد الفئات السكانية لاختبار عدوى السل الكامنة والعلاج الوقائي من السل (المتعايشون مع فيروس العوز المناعي البشري، والمخالطون المنزليون، والفئات الأخرى المعرضة للخطر)، وخوارزميات استبعاد مرض السل النشط، واختبار عدوى السل الكامنة، وخيارات العلاج الوقائي من السل.",
        "zh": "本表列出世卫组织结核病预防性治疗综合指南中的18项建议。这些建议分为以下几组：确定需进行潜伏结核感染检测和结核病预防性治疗的人群（艾滋病毒感染者、家庭接触者、其他高危人群）、排除活动性结核病的算法、潜伏结核感染检测以及结核病预防性治疗方案。",
        "es": "El cuadro enumera las 18 recomendaciones de las directrices unificadas de la OMS sobre el tratamiento preventivo de la tuberculosis. Están agrupadas en: identificación de las poblaciones para la prueba de la ITBL y el tratamiento preventivo (personas con el VIH, contactos domiciliarios, otras personas en riesgo), algoritmos para descartar la tuberculosis activa, pruebas de la ITBL y opciones de tratamiento preventivo de la tuberculosis.",
        "fr": "Le tableau énumère les 18 recommandations des lignes directrices unifiées de l’OMS sur le traitement préventif de la tuberculose. Elles sont regroupées sous : identification des populations à soumettre au dépistage de l’infection tuberculeuse latente et au traitement préventif (personnes vivant avec le VIH, contacts familiaux, autres personnes à risque), algorithmes permettant d’exclure une tuberculose évolutive, dépistage de l’infection tuberculeuse latente et options de traitement préventif.",
        "ru": "В таблице перечислены 18 рекомендаций сводного руководства ВОЗ по профилактическому лечению туберкулеза. Они сгруппированы по разделам: определение групп населения для тестирования на латентную туберкулезную инфекцию и профилактического лечения (люди, живущие с ВИЧ, домашние контакты, другие группы риска), алгоритмы исключения активного туберкулеза, тестирование на латентную туберкулезную инфекцию и варианты профилактического лечения туберкулеза."
      },
      "csv": "tables/table-1-1.csv"
    },
    {
      "label": "Table 3.1",
      "caption": "Table 3.1: Key steps in ruling out TB and considering TPT",
      "pages": [
        35
      ],
      "columns": [
        {
          "titles": ""
        },
        {
          "titles": "Adults and adolescents living with HIVᵇ"
        },
        {
          "titles": "Children living with HIVᵃ"
        },
        {
          "titles": "HIV-negative household / close contacts of TB patients"
        },
        {
          "titles": "Clinical at-risk populations"
        }
      ],
      "rows": [
        [
          "Clinical symptom-based screeningᵃ",
          "Current cough, fever, weight loss or night sweats",
          "Absence or poor weight gain, fever or current cough or history of contact with a case of TB, reduced playfulness, night sweats",
          "Cough of any duration, haemoptysis, fever, night sweats, weight loss, chest pain, shortness of breath, fatigue",
          ""
        ],
        [
          "Frequency of symptom screening",
          "At every visit to a health facility or contact with a health worker",
          "",
          "",
          ""
        ],
        [
          "Chest radiography",
          "Not mandatory although desirable. May be considered among PLHIV on ART; among asymptomatic adolescent and adult contacts and clinical at-risk groups where facilities are available and human resources and health system capacity permits",
          "",
          "",
          ""
        ],
        [
          "Diagnostic testing for TB if screen test is positive",
          "WHO recommends rapid diagnostics (such as Xpert MTB/Rif, urine lipoarabinomannan assay among seriously ill PLHIV) or as per national guidelines",
          "",
          "",
          ""
        ],
        [
          "Test for TB infection (TST or IGRA)",
          "Not required among PLHIV and contacts below five years of age. In other populations these tests limit unnecessary treatment of uninfected individuals (such as settings with low prevalence of TB infection) Unavailability of tests should not be a barrier to provision of TPT to those in need",
          "",
          "",
          ""
        ],
        [
          "Contraindication to TPT",
          "• Active hepatitis (acute or chronic), regular and heavy alcohol consumption and symptoms of peripheral neuropathy • Concurrent use of other hepatotoxic medications (such as nevirapine) • History of hypersensitivity to TPT",
          "",
          "",
          ""
        ],
        [
          "Counselling",
          "Information on TB infection, need for TPT, schedule of medication collection, medication adherence support and follow-up visits, benefits from completing the course, adverse events, actions on development of TB symptoms or adverse events",
          "",
          "",
          ""
        ]
      ],
      "notes": "a Screening for children and pregnant or breastfeeding women may be integrated into various entry points for care (such as maternal and child health, immunization, well baby clinics, nutrition clinics). b Among PLHIV, all the above steps should be incorporated if differentiated HIV service delivery models are implemented. ACF and TPT should be an integral part of the care package for PLHIV.",
      "narratives": {
        "en": "The table sets out the key steps in ruling out TB disease and considering TB preventive treatment, from clinical symptom-based screening to chest radiography, diagnostic testing, testing for TB infection, contraindications and counselling. Symptom screening criteria are given separately for adults and adolescents living with HIV, children living with HIV, and HIV-negative household contacts and clinical at-risk populations; the other steps apply to all groups.",
        "ar": "يعرض الجدول الخطوات الرئيسية لاستبعاد مرض السل والنظر في العلاج الوقائي من السل، بدءاً من الفحص القائم على الأعراض السريرية مروراً بالتصوير الشعاعي للصدر والاختبار التشخيصي واختبار عدوى السل وموانع الاستعمال وصولاً إلى المشورة. وتُعرض معايير فحص الأعراض بشكل منفصل للبالغين والمراهقين المتعايشين مع فيروس العوز المناعي البشري، والأطفال المتعايشين مع الفيروس، والمخالطين المنزليين غير المصابين بالفيروس والفئات المعرضة للخطر سريرياً؛ أما الخطوات الأخرى فتنطبق على جميع الفئات.",
        "zh": "本表列出排除结核病并考虑结核病预防性治疗的关键步骤，从基于临床症状的筛查到胸部X线检查、诊断检测、结核感染检测、禁忌症和咨询。症状筛查标准分别针对感染艾滋病毒的成人和青少年、感染艾滋病毒的儿童，以及艾滋病毒阴性的家庭接触者和临床高危人群列出；其他步骤适用于所有人群。",
        "es": "El cuadro expone los pasos clave para descartar la tuberculosis y considerar el tratamiento preventivo, desde el cribado basado en síntomas clínicos hasta la radiografía de tórax, las pruebas diagnósticas, las pruebas de infección tuberculosa, las contraindicaciones y el asesoramiento. Los criterios de cribado de síntomas se indican por separado para adultos y adolescentes con el VIH, niños con el VIH, y contactos domiciliarios VIH-negativos y poblaciones clínicas en riesgo; los demás pasos se aplican a todos los grupos.",
        "fr": "Le tableau présente les étapes clés pour exclure une tuberculose et envisager un traitement préventif, du dépistage fondé sur les symptômes cliniques à la radiographie thoracique, aux tests diagnostiques, au dépistage de l’infection tuberculeuse, aux contre-indications et au conseil. Les critères de dépistage des symptômes sont indiqués séparément pour les adultes et adolescents vivant avec le VIH, les enfants vivant avec le VIH, et les contacts familiaux séronégatifs et les populations cliniquement à risque ; les autres étapes s’appliquent à tous les groupes.",
        "ru": "В таблице изложены ключевые шаги по исключению туберкулеза и рассмотрению профилактического лечения — от скрининга на основе клинических симптомов до рентгенографии грудной клетки, диагностического тестирования, тестирования на туберкулезную инфекцию, противопоказаний и консультирования. Критерии скрининга симптомов приводятся отдельно для взрослых и подростков, живущих с ВИЧ, детей, живущих с ВИЧ, а также ВИЧ-отрицательных домашних контактов и клинических групп риска; остальные шаги применяются ко всем группам."
      },
      "csv": "tables/table-3-1.csv"
    },
    {
      "label": "Table 4.1",
      "caption": "Table 4.1: Characteristic features of TST and IGRA (43)",
      "pages": [
        42,
        43
      ],
      "columns": [
        {
          "titles": ""
        },
        {
          "titles": "TST"
        },
        {
          "titles": "IGRA"
        }
      ],
      "rows": [
        [
          "Test requirements",
          "• A valid TST requires proper intradermal administration of 0.1 ml of tuberculin-PPD into the volar surface of the forearm • PPD requires cold chain • Trained staff are required to administer and read skin induration • Needs to be read within 48–72 hours",
          "• IGRAs are in vitro blood tests that detect interferon gamma in blood using ELISA • Requires fresh blood specimens to mix with antigens and controls, to be processed within 8–30 hours after collection while white blood cells are viable • Need an efficient sample transport mechanism • Need different blood collection tubes for different altitudes"
        ],
        [
          "Potential inaccuracy",
          "• False-positive TSTs can result from contact with nontuberculous mycobacteria or vaccination with bacille Calmette-Guérin (BCG) • Potential for inaccuracies and bias in reading skin induration • False negatives in immuno-deficiency conditions",
          "• Delay in transportation of blood specimen • Errors in processing of blood specimen • Wrong interpretation of assay • False-negative results likely in immuno-deficiency conditions, faded immune memory, technical-operational variability, and in children below two years of age"
        ],
        [
          "Advantages",
          "• Can be performed in the field • Significantly fewer resource needs compared to IGRA • No laboratory setup required • More familiar to practitioners in resource-constrained settings",
          "• Single visit required to conduct test; however, test result may be shared with the person on the second visit, when like the TST, clinical management decisions are made • Results possible within 24 hours • No booster effect • No false-positive results due to BCG"
        ],
        [
          "Challenges",
          "• Need for training in intradermal injection, reading and interpretation • Second visit (by individual or heath care worker) required for test reading • Recurrent global shortages and stock-outs of quality assured PPD • Requirement for cold chain • Repeat test (two-step testing) for individuals whose immunity may have waned",
          "• Higher test cost • Need for phlebotomy • Need sophisticated laboratory equipment, highly skilled laboratory personnel to perform and interpret test results • Potential for delays in sample transportation due to long distances to laboratories that offer IGRA testing • Processing and results take at least one day (often longer), hence the person may need to return to collect results • If the laboratory SOP requires batching of tests to reduce costs there may be delays in reporting results beyond a week"
        ],
        [
          "Preferred test",
          "• Children less than two years of age • Settings with poor laboratory infrastructure",
          "• Persons who have received BCG (either as a vaccine or for cancer therapy), although this is less applicable in adults who received BCG as infants due to waning of effect • Groups that are unlikely or unable to return for TST reading, such as homeless persons and people who use drugs or due to reasons like long distance, job security, or other pressing commitments"
        ]
      ],
      "narratives": {
        "en": "The table compares the tuberculin skin test (TST) and interferon-gamma release assays (IGRA) for detecting TB infection. Rows cover test requirements, potential inaccuracy, advantages, challenges and the situations in which each test is preferred.",
        "ar": "يقارن الجدول بين اختبار السلين الجلدي ومقايسات إطلاق الإنترفيرون غاما للكشف عن عدوى السل. وتتناول الصفوف متطلبات الاختبار، واحتمالات عدم الدقة، والمزايا، والتحديات، والحالات التي يُفضَّل فيها كل اختبار.",
        "zh": "本表比较用于检测结核感染的结核菌素皮肤试验与γ干扰素释放试验。各行涵盖检测要求、潜在不准确性、优点、挑战以及各项检测的首选情形。",
        "es": "El cuadro compara la prueba cutánea de la tuberculina (PCT) y los ensayos de liberación de interferón gamma (IGRA) para detectar la infección tuberculosa. Las filas abarcan los requisitos de la prueba, la posible inexactitud, las ventajas, los retos y las situaciones en que se prefiere cada prueba.",
        "fr": "Le tableau compare l’intradermoréaction à la tuberculine (IDR) et les tests de libération d’interféron gamma (IGRA) pour la détection de l’infection tuberculeuse. Les lignes portent sur les exigences du test, les inexactitudes possibles, les avantages, les difficultés et les situations dans lesquelles chaque test est privilégié.",
        "ru": "В таблице сравниваются туберкулиновая кожная проба и тесты высвобождения гамма-интерферона для выявления туберкулезной инфекции. Строки охватывают требования к тесту, возможную неточность, преимущества, трудности и ситуации, в которых предпочтителен каждый тест."
      },
      "csv": "tables/table-4-1.csv"
    },
    {
      "label": "Table 5.2",
      "caption": "Table 5.2: Recommended dosages of medicines for TB preventive treatment",
      "pages": [
        52,
        53
      ],
      "columns": [
        {
          "titles": "Regimen"
        },
        {
          "titles": "Dose by age and weight band"
        },
        {
          "titles": ""
        },
        {
          "titles": ""
        },
        {
          "titles": ""
        },
        {
          "titles": ""
        }
      ],
      "rows": [
        [
          "6 or 9 months of daily isoniazid monotherapy (6H, 9H)ᵃ",
          "Age 10 years & older: 5 mg/kg/day Age < 10 years: 10 mg/kg/day (range, 7–15 mg)",
          "",
          "",
          "",
          ""
        ],
        [
          "Four months of daily rifampicin (4R)",
          "Age 10 years & older: 10 mg/kg/day Age < 10 years: 15 mg/kg/day (range, 10–20 mg)",
          "",
          "",
          "",
          ""
        ],
        [
          "Three months of daily rifampicin plus isoniazid (3HR)",
          "Isoniazid: Age 10 years & older: 5 mg/kg/day Age < 10 years: 10 mg/kg/day (range, 7–15 mg) Rifampicin: Age 10 years & older: 10 mg/kg/day Age < 10 years: 15 mg/kg/day (range, 10–20 mg)",
          "",
          "",
          "",
          ""
        ],
        [
          "",
          "4–7 kg",
          "8–11 kg",
          "12–15 kg",
          "16–24 kg",
          "> 25 kg"
        ],
        [
          "",
          "1",
          "2",
          "3",
          "4",
          "Use adult formulations"
        ],
        [
          "Three months of rifapentine plus high dose isoniazid weekly (12 doses) (3HP)",
          "Age 2–14 yearsᵈ",
          "",
          "",
          "",
          ""
        ],
        [
          "",
          "10–15 kg",
          "16–23 kg",
          "24–30 kg",
          "31–34 kg",
          "> 34 kg"
        ],
        [
          "",
          "3",
          "5",
          "6",
          "7",
          "7"
        ],
        [
          "",
          "2",
          "3",
          "4",
          "5",
          "5"
        ],
        [
          "",
          "2",
          "3",
          "4",
          "5",
          "5"
        ],
        [
          "",
          "Age > 14 yearsᵈ",
          "",
          "",
          "",
          ""
        ],
        [
          "",
          "30–35 kg",
          "36–45 kg",
          "46–55 kg",
          "56–70 kg",
          "> 70 kg"
        ],
        [
          "",
          "3",
          "3",
          "3",
          "3",
          "3"
        ],
        [
          "",
          "6",
          "6",
          "6",
          "6",
          "6"
        ],
        [
          "",
          "3",
          "3",
          "3",
          "3",
          "3"
        ],
        [
          "One month of rifapentine plus isoniazid daily (28 doses) (1HP)",
          "Age ≥ 13 years (regardless of weight band) Isoniazid 300 mg/day Rifapentine 600 mg/day",
          "",
          "",
          "",
          ""
        ],
        [
          "Six months of levofloxacin daily (preventive treatment of MDR-TB)",
          "Age > 14 years, by body weight: < 46 kg, 750 mg/day; > 45 kg, 1g/day Age < 15 yearsᵉ (range approx. 15–20 mg/kg/day), by body weight: 5–9 kg: 150 mg/day; 10–15 kg: 200–300mg/day; 16–23 kg: 300–400mg/day; 24–34 kg: 500–750mg/day",
          "",
          "",
          "",
          ""
        ]
      ],
      "notes": "a A triple pill combination containing isoniazid 300 mg + pyridoxine 25 mg + sulfamethoxazole 800 mg + trimethoprim 160 mg (scored) is the preferred alternative regimen for PLHIV being considered for isoniazid monotherapy (1 pill daily for adults, half pill for children 5 years and older of age and quarter for children < 5 years of age). b 300 mg formulation can be used to reduce the pill burden. c Expected to become available in a near future. d Dosage may differ among adults and children in overlapping weight-bands. e Levofloxacin 100 mg dispersible tablets available for children. [Transcriber: the 'Dose by age and weight band' header spans columns B–F; weight-band sub-tables nested in the dose column are laid out on columns B–F.]",
      "narratives": {
        "en": "The table gives the recommended dosages of medicines for each TB preventive treatment regimen (6H/9H, 4R, 3HR, 3HP, 1HP and six months of levofloxacin for MDR-TB contacts) by age and weight band. For 3HR and 3HP it includes weight-band tables showing the number of tablets of each medicine and formulation.",
        "ar": "يعرض الجدول الجرعات الموصى بها من الأدوية لكل نظام من نظم العلاج الوقائي من السل (6H/9H و4R و3HR و3HP و1HP، وستة أشهر من الليفوفلوكساسين لمخالطي مرضى السل المقاوم للأدوية المتعددة) حسب العمر وفئة الوزن. ويتضمن بالنسبة إلى نظامي 3HR و3HP جداول حسب فئات الوزن تبيّن عدد أقراص كل دواء وتركيبة.",
        "zh": "本表按年龄和体重区间列出各结核病预防性治疗方案（6H/9H、4R、3HR、3HP、1HP以及针对耐多药结核病接触者的六个月左氧氟沙星）的推荐药物剂量。对于3HR和3HP，表中包含按体重区间列出每种药物和剂型片数的子表。",
        "es": "El cuadro indica las dosis recomendadas de los medicamentos para cada pauta de tratamiento preventivo de la tuberculosis (6H/9H, 4R, 3HR, 3HP, 1HP y seis meses de levofloxacino para contactos de casos de TB-MDR) según la edad y la franja de peso. Para 3HR y 3HP incluye tablas por franja de peso con el número de comprimidos de cada medicamento y formulación.",
        "fr": "Le tableau indique les posologies recommandées des médicaments pour chaque schéma de traitement préventif de la tuberculose (6H/9H, 4R, 3HR, 3HP, 1HP et six mois de lévofloxacine pour les contacts de cas de tuberculose multirésistante) selon l’âge et la tranche de poids. Pour 3HR et 3HP, il comprend des tableaux par tranche de poids indiquant le nombre de comprimés de chaque médicament et formulation.",
        "ru": "В таблице приведены рекомендуемые дозировки лекарственных средств для каждой схемы профилактического лечения туберкулеза (6H/9H, 4R, 3HR, 3HP, 1HP и шесть месяцев левофлоксацина для контактов больных МЛУ-ТБ) в зависимости от возраста и весовой категории. Для 3HR и 3HP включены таблицы по весовым категориям с количеством таблеток каждого препарата и лекарственной формы."
      },
      "csv": "tables/table-5-2.csv"
    },
    {
      "label": "Table 5.3",
      "caption": "Table 5.3: Preventive TB treatment completion",
      "pages": [
        58
      ],
      "columns": [
        {
          "titles": ""
        },
        {
          "titles": "Total duration (months)"
        },
        {
          "titles": "Expected number of doses"
        },
        {
          "titles": "80% of recommended doses (days)"
        },
        {
          "titles": "Extended time for treatment completion (days) (treatment duration +33% additional time)"
        }
      ],
      "rows": [
        [
          "6H (daily)",
          "6",
          "182",
          "146",
          "239"
        ],
        [
          "3HR (daily)",
          "3",
          "84",
          "68",
          "120"
        ],
        [
          "3HP (weekly)",
          "3",
          "12",
          "11ᵃ",
          "120"
        ],
        [
          "4R (daily)",
          "4",
          "120",
          "96",
          "160"
        ],
        [
          "1HP (daily)",
          "1",
          "28",
          "23",
          "40"
        ]
      ],
      "notes": "a 90% of recommended number of doses",
      "narratives": {
        "en": "The table summarizes the recommended TB preventive treatment regimens and suggested criteria for assessing treatment completion. For each regimen it gives the total duration in months, the expected number of doses, 80% of recommended doses, and the extended time allowed for completion (treatment duration plus 33%).",
        "ar": "يلخص الجدول نظم العلاج الوقائي من السل الموصى بها والمعايير المقترحة لتقييم إتمام العلاج. ويذكر لكل نظام المدة الإجمالية بالأشهر، والعدد المتوقع من الجرعات، ونسبة 80% من الجرعات الموصى بها، والمدة الممددة المسموح بها لإتمام العلاج (مدة العلاج مضافاً إليها 33%).",
        "zh": "本表汇总推荐的结核病预防性治疗方案以及评估治疗完成情况的建议标准。表中对每个方案给出总疗程（月）、预期剂量数、推荐剂量的80%以及允许完成治疗的延长时间（疗程加33%）。",
        "es": "El cuadro resume las pautas recomendadas de tratamiento preventivo de la tuberculosis y los criterios propuestos para evaluar la finalización del tratamiento. Para cada pauta indica la duración total en meses, el número previsto de dosis, el 80% de las dosis recomendadas y el plazo ampliado para completar el tratamiento (duración del tratamiento más un 33%).",
        "fr": "Le tableau résume les schémas recommandés de traitement préventif de la tuberculose et les critères proposés pour évaluer l’achèvement du traitement. Pour chaque schéma, il indique la durée totale en mois, le nombre de doses attendu, 80 % des doses recommandées et le délai prolongé accordé pour achever le traitement (durée du traitement plus 33 %).",
        "ru": "В таблице обобщены рекомендуемые схемы профилактического лечения туберкулеза и предлагаемые критерии оценки завершения лечения. Для каждой схемы указаны общая продолжительность в месяцах, ожидаемое число доз, 80% рекомендуемых доз и продленный срок для завершения лечения (продолжительность лечения плюс 33%)."
      },
      "csv": "tables/table-5-3.csv"
    },
    {
      "label": "Table 6.1",
      "caption": "Table 6.1: Likely adverse events with drugs used for TPT",
      "pages": [
        68
      ],
      "columns": [
        {
          "titles": ""
        },
        {
          "titles": "Known adverse events"
        },
        {
          "titles": "Rare adverse events"
        }
      ],
      "rows": [
        [
          "Isoniazid",
          "Asymptomatic elevation of serum liver enzyme concentrations; Hepatitis; Peripheral neuropathy (paraesthesia, numbness and limb pain); Skin rash; Sleepiness and lethargy",
          "Convulsions; Pellagra; Arthralgia; Anaemia; Lupoid reactions"
        ],
        [
          "Rifampicin",
          "Gastrointestinal reactions (abdominal pain, nausea, vomiting); Hepatitis; Generalized cutaneous reactions; Thrombocytopenic purpura; Discolouration of body fluids",
          "Osteomalacia; Pseudomembranous colitis; Pseudoadrenal crisis; Acute renal failure; Shock; Haemolytic anaemia; Flu-like syndrome"
        ],
        [
          "Rifapentine",
          "Gastrointestinal reactions (abdominal pain, nausea, vomiting); Hypersensitivity reactions (flu-like symptoms); Hepatitis; Discolouration of body fluids",
          "Hypotension/syncope; Decrease in white blood cell and red blood cell count; Decreased appetite; Hyperbilirubinemia"
        ]
      ],
      "notes": "[Transcriber: items printed on separate lines within a cell are separated here by '; '.]",
      "narratives": {
        "en": "The table lists the likely adverse events of the drugs used for TB preventive treatment. For isoniazid, rifampicin and rifapentine it separates known adverse events from rare adverse events.",
        "ar": "يسرد الجدول الأحداث الضائرة المحتملة للأدوية المستخدمة في العلاج الوقائي من السل. ويميّز بالنسبة إلى الإيزونيازيد والريفامبيسين والريفابنتين بين الأحداث الضائرة المعروفة والأحداث الضائرة النادرة.",
        "zh": "本表列出结核病预防性治疗所用药物可能出现的不良事件。对于异烟肼、利福平和利福喷丁，表中分别列出已知不良事件和罕见不良事件。",
        "es": "El cuadro enumera los eventos adversos probables de los medicamentos utilizados en el tratamiento preventivo de la tuberculosis. Para la isoniazida, la rifampicina y la rifapentina distingue los eventos adversos conocidos de los raros.",
        "fr": "Le tableau énumère les événements indésirables probables des médicaments utilisés pour le traitement préventif de la tuberculose. Pour l’isoniazide, la rifampicine et la rifapentine, il distingue les événements indésirables connus des événements indésirables rares.",
        "ru": "В таблице перечислены вероятные нежелательные явления при приеме препаратов для профилактического лечения туберкулеза. Для изониазида, рифампицина и рифапентина известные нежелательные явления отделены от редких."
      },
      "csv": "tables/table-6-1.csv"
    },
    {
      "label": "Table 6.2",
      "caption": "Table 6.2: Summary of adverse events and treatment withdrawals because of adverse events",
      "pages": [
        70
      ],
      "columns": [
        {
          "titles": "Regimen"
        },
        {
          "titles": "Participants in studies included in the systematic review"
        },
        {
          "titles": "Median percentage of study participants experiencing adverse events (minimum–maximum)"
        }
      ],
      "rows": [
        [
          "Any adverse events",
          "",
          ""
        ],
        [
          "6Hᵃ",
          "1098",
          "36.1% (6%–63.4%)"
        ],
        [
          "9H",
          "4482",
          "17.6% (0.18%–71.8%)"
        ],
        [
          "3HP",
          "4991",
          "11.5% (1.9%–41.5%)"
        ],
        [
          "3–4R",
          "838",
          "20.0% (0.2%–57.4%)"
        ],
        [
          "3–4HR",
          "745",
          "29.7% (12.2%–41.3%)"
        ],
        [
          "Grade 3–4 adverse eventsᵇ",
          "",
          ""
        ],
        [
          "6H",
          "880",
          "8.2% (0.0%–12.0%)"
        ],
        [
          "9H",
          "4714",
          "3.3% (0.0%–6.5%)"
        ],
        [
          "3HP",
          "5787",
          "6.0% (1.3%–8.9%)"
        ],
        [
          "3–4R",
          "788",
          "1.7% (1.7%–2.1%)"
        ],
        [
          "3–4HR",
          "1023",
          "2.3% (NA)"
        ],
        [
          "Withdrawn from study because of adverse events",
          "",
          ""
        ],
        [
          "6H",
          "1738",
          "3.8% (0.0%–12.0%)"
        ],
        [
          "9H",
          "5304",
          "6.4% (0.0%–16.8%)"
        ],
        [
          "3HP",
          "5993",
          "1.7% (0.5%–4.9%)"
        ],
        [
          "3–4R",
          "846",
          "2.8% (1.7%–10.1%)"
        ],
        [
          "3–4HR",
          "1797",
          "2.2% (0.0%–7.3%)"
        ]
      ],
      "notes": "a H-isoniazid, R-rifampicin, P-rifapentine b Grade-3 adverse event: medically significant but not an imminently life-threatening event. Grade-4 adverse event: life-threatening event.",
      "narratives": {
        "en": "The table summarizes, by TB preventive treatment regimen (6H, 9H, 3HP, 3–4R, 3–4HR), the number of participants in studies included in a systematic review and the median percentage (minimum–maximum) experiencing adverse events. Results are given separately for any adverse events, grade 3–4 adverse events, and withdrawal from the study because of adverse events.",
        "ar": "يلخص الجدول، حسب نظام العلاج الوقائي من السل (6H و9H و3HP و3–4R و3–4HR)، عدد المشاركين في الدراسات المشمولة في استعراض منهجي والنسبة المئوية الوسيطة (الحد الأدنى–الحد الأقصى) لمن تعرضوا لأحداث ضائرة. وتُعرض النتائج بشكل منفصل لأي أحداث ضائرة، والأحداث الضائرة من الدرجة 3–4، والانسحاب من الدراسة بسبب الأحداث الضائرة.",
        "zh": "本表按结核病预防性治疗方案（6H、9H、3HP、3–4R、3–4HR）汇总系统评价所纳入研究的参与者人数，以及发生不良事件的参与者百分比中位数（最小值–最大值）。结果分别列出任何不良事件、3–4级不良事件以及因不良事件退出研究的情况。",
        "es": "El cuadro resume, por pauta de tratamiento preventivo de la tuberculosis (6H, 9H, 3HP, 3–4R, 3–4HR), el número de participantes en los estudios incluidos en una revisión sistemática y el porcentaje mediano (mínimo–máximo) que presentó eventos adversos. Los resultados se presentan por separado para cualquier evento adverso, eventos adversos de grado 3–4 y retirada del estudio por eventos adversos.",
        "fr": "Le tableau résume, par schéma de traitement préventif de la tuberculose (6H, 9H, 3HP, 3–4R, 3–4HR), le nombre de participants aux études incluses dans une revue systématique et le pourcentage médian (minimum–maximum) ayant présenté des événements indésirables. Les résultats sont présentés séparément pour tout événement indésirable, les événements indésirables de grade 3–4 et le retrait de l’étude en raison d’événements indésirables.",
        "ru": "В таблице обобщены по схемам профилактического лечения туберкулеза (6H, 9H, 3HP, 3–4R, 3–4HR) число участников исследований, включенных в систематический обзор, и медианная доля (минимум–максимум) участников с нежелательными явлениями. Результаты приводятся отдельно для любых нежелательных явлений, нежелательных явлений 3–4 степени и выбывания из исследования из-за нежелательных явлений."
      },
      "csv": "tables/table-6-2.csv"
    },
    {
      "label": "Table 6.3",
      "caption": "Table 6.3: Management of potential adverse reactions following treatment with 3HP⁹",
      "pages": [
        72,
        73
      ],
      "columns": [
        {
          "titles": "Adverse event"
        },
        {
          "titles": "Stop and consider reintroduction with caution"
        },
        {
          "titles": "Stop and do not reintroduce"
        }
      ],
      "rows": [
        [
          "Flu-like syndrome (attacks of fever, chills and malaise, sometimes with headache, dizziness or bone pain)",
          "If mild and not increasing, continue treatment and observe closely",
          "If moderate to severe symptoms, consider alternative TPT options without a rifamycin (such as 6H)"
        ],
        [
          "Drug-associated fever only",
          "Consider reintroduction if fever settles below 39°C, but stop permanently if fever recurs",
          "If fever > 39°C after previous episode of drug-associated fever"
        ],
        [
          "Persistent nausea, frequent vomiting and/or persistent episodes of unformed watery stools",
          "• Administer antiemetic or antidiarrhoeal medication • Consider reintroducing 3HP with caution once the symptoms have resolved",
          "If there is nausea, vomiting or diarrhoea which requires aggressive rehydration"
        ],
        [
          "Cutaneous reactions",
          "• Diffuse rash (no vesicles) • Diffuse rash with limited vesicles",
          "If there are extensive bullous lesions/ulceration of mucous membranes/Stevens Johnson or toxic epidermal necrolysis, contact a specialist and use steroids"
        ],
        [
          "Other hypersensitivity reactions (hypotension, acute bronchospasm, conjunctivitis, thrombocytopenia)",
          "Assess the clinical severity of the symptoms and if severe consider alternative TPT options without a rifamycin (6H)",
          ""
        ],
        [
          "Hepatitis (early symptoms weakness, fatigue, loss of appetite, persistent nausea)",
          "Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) < 5 times the upper limits of normal and absence of symptoms",
          "• ALT/AST is ≥ 5 times the upper limit of normal in the absence of symptoms • ALT/AST is ≥ 3 times the upper limit of normal in the presence of symptoms"
        ],
        [
          "Psychosis",
          "Psychiatric evaluation, antipsychotic therapy, pyridoxine",
          "Attributable to isoniazid"
        ],
        [
          "Seizures",
          "Withhold isoniazid pending resolution of seizures, evaluate possible causes of seizures (104)",
          "Attributable to isoniazid"
        ]
      ],
      "notes": "⁹ Most adverse drug reactions associated with HP regimens are mild, self-resolving and without sequelae. [Transcriber: '39°C' is printed with a superscript o.]",
      "narratives": {
        "en": "The table guides the management of potential adverse reactions after treatment with 3HP (weekly isoniazid plus rifapentine). For each adverse event it indicates when to stop and consider reintroducing treatment with caution and when to stop and not reintroduce.",
        "ar": "يقدم الجدول إرشادات بشأن التعامل مع التفاعلات الضائرة المحتملة بعد العلاج بنظام 3HP (الإيزونيازيد مع الريفابنتين أسبوعياً). ويبيّن لكل حدث ضائر متى يُوقف العلاج مع النظر في إعادة إدخاله بحذر، ومتى يُوقف دون إعادة إدخاله.",
        "zh": "本表为3HP（每周异烟肼加利福喷丁）治疗后潜在不良反应的处理提供指导。表中对每种不良事件说明何时停药并考虑谨慎重新用药，以及何时停药且不再重新用药。",
        "es": "El cuadro orienta sobre el manejo de las posibles reacciones adversas tras el tratamiento con 3HP (isoniazida más rifapentina semanal). Para cada evento adverso indica cuándo suspender y considerar la reintroducción con precaución y cuándo suspender sin reintroducir.",
        "fr": "Le tableau donne des orientations pour la prise en charge des réactions indésirables possibles après un traitement par 3HP (isoniazide plus rifapentine une fois par semaine). Pour chaque événement indésirable, il indique quand arrêter et envisager une réintroduction prudente et quand arrêter sans réintroduire.",
        "ru": "В таблице даны рекомендации по ведению возможных нежелательных реакций после лечения по схеме 3HP (изониазид плюс рифапентин еженедельно). Для каждого нежелательного явления указано, когда следует прекратить прием и рассмотреть осторожное возобновление, а когда прекратить без возобновления."
      },
      "csv": "tables/table-6-3.csv"
    },
    {
      "label": "Table 6.4",
      "caption": "Table 6.4: Common drug–drug interactions of isoniazid and rifamycins",
      "pages": [
        75,
        76,
        77
      ],
      "columns": [
        {
          "titles": "Medication class"
        },
        {
          "titles": "Examples"
        },
        {
          "titles": "Isoniazid inhibits metabolism and increases blood levels"
        },
        {
          "titles": "Rifamycins accelerate metabolism and decrease blood levels¹⁰"
        }
      ],
      "rows": [
        [
          "Antiarrhythmics",
          "Disopyramide/mexiletine/quinidine/tocainide",
          "",
          "↓"
        ],
        [
          "Antibiotics",
          "Chloramphenicol/clarithromycin/dapsone/doxycycline/fluoroquinolones",
          "",
          "↓"
        ],
        [
          "Anticoagulants",
          "Warfarin",
          "↑",
          "↓"
        ],
        [
          "Anticonvulsants",
          "Phenytoin",
          "↑ (Phenytoin, carbamazepine, primidone, valproic acid)",
          "↓"
        ],
        [
          "Antidepressants",
          "Amitriptyline/nortriptyline",
          "↑ Some SSRI (selective serotonin reuptake inhibitors)",
          "↓"
        ],
        [
          "Antimalarials",
          "",
          "↑ Halofantrine",
          "↓ Quinine"
        ],
        [
          "Antipsychotics",
          "Haloperidol",
          "↑",
          "↓"
        ],
        [
          "Antivirals",
          "",
          "↑ Ritonavir (ARV) ↑ Efavirenz",
          "↓ PI, INSTI ↓ Nevirapine with rifampicin"
        ],
        [
          "Azole antifungals",
          "Fluconazole/itraconazole/ketoconazole",
          "↑",
          "↓"
        ],
        [
          "Barbiturates",
          "Phenobarbital",
          "",
          "↓"
        ],
        [
          "Benzodiazepines",
          "Diazepam",
          "↑ Diazepam, triazolam",
          "↓"
        ],
        [
          "Beta-blockers",
          "Propranolol",
          "",
          "↓"
        ],
        [
          "Calcium channel blockers",
          "Diltiazem/nifedipine/verapamil",
          "",
          "↓"
        ],
        [
          "Cardiac glycoside preparations",
          "Digoxin",
          "",
          "↓"
        ],
        [
          "Corticosteroids",
          "Prednisone",
          "",
          "↓"
        ],
        [
          "Fibrates",
          "Clofibrate",
          "",
          "↓"
        ],
        [
          "Oral hypoglycaemic agents",
          "Sulfonylureas",
          "",
          "↓"
        ],
        [
          "Hormonal contraceptives/progestins",
          "Ethinyl oestradiol/levonorgestrel",
          "",
          "↓ (Rifapentine)"
        ],
        [
          "Immunosuppressants",
          "Cyclosporine/tacrolimus",
          "",
          "↓"
        ],
        [
          "Methylxanthines",
          "Theophylline",
          "↑",
          "↓"
        ],
        [
          "Narcotic analgesics",
          "Methadone",
          "↑ Levomethyldate acetate",
          "↓"
        ],
        [
          "Phosphodiesterase-5 (PDE-5) Inhibitors",
          "Sildenafil",
          "",
          "↓ (Rifapentine)"
        ],
        [
          "Thyroid preparations",
          "Levothyroxine",
          "",
          "↓"
        ]
      ],
      "notes": "¹⁰ For many agents the magnitude may depend upon daily dosing of rifamycins versus once weekly dose (rifapentine). [Transcriber: ↑ and ↓ are the arrow symbols printed in the table.]",
      "narratives": {
        "en": "The table lists common drug–drug interactions of isoniazid and rifamycins by medication class, with example drugs. Arrows show where isoniazid inhibits metabolism and increases blood levels, and where rifamycins accelerate metabolism and decrease blood levels.",
        "ar": "يسرد الجدول التداخلات الدوائية الشائعة للإيزونيازيد والريفاميسينات حسب فئة الأدوية، مع أمثلة على الأدوية. وتبيّن الأسهم الحالات التي يثبط فيها الإيزونيازيد الاستقلاب ويرفع المستويات في الدم، والحالات التي تسرّع فيها الريفاميسينات الاستقلاب وتخفض المستويات في الدم.",
        "zh": "本表按药物类别列出异烟肼和利福霉素类药物常见的药物相互作用，并给出药物示例。箭头表示异烟肼抑制代谢并升高血药浓度的情况，以及利福霉素类药物加速代谢并降低血药浓度的情况。",
        "es": "El cuadro enumera las interacciones farmacológicas frecuentes de la isoniazida y las rifamicinas por clase de medicamento, con ejemplos. Las flechas indican cuándo la isoniazida inhibe el metabolismo y aumenta las concentraciones sanguíneas, y cuándo las rifamicinas aceleran el metabolismo y reducen las concentraciones sanguíneas.",
        "fr": "Le tableau énumère les interactions médicamenteuses courantes de l’isoniazide et des rifamycines par classe de médicaments, avec des exemples. Les flèches indiquent les cas où l’isoniazide inhibe le métabolisme et augmente les concentrations sanguines, et ceux où les rifamycines accélèrent le métabolisme et diminuent les concentrations sanguines.",
        "ru": "В таблице перечислены распространенные лекарственные взаимодействия изониазида и рифамицинов по классам препаратов с примерами. Стрелки показывают, когда изониазид подавляет метаболизм и повышает концентрацию в крови, а когда рифамицины ускоряют метаболизм и снижают концентрацию в крови."
      },
      "csv": "tables/table-6-4.csv"
    }
  ],
  "coverage": [
    {
      "kind": "contents",
      "state": "found",
      "count": 19,
      "note": "outline"
    },
    {
      "kind": "sections",
      "state": "found",
      "count": 20,
      "note": "2 levels"
    },
    {
      "kind": "figures",
      "state": "found",
      "count": 15
    },
    {
      "kind": "tables",
      "state": "found",
      "count": 9
    },
    {
      "kind": "references",
      "state": "not-extracted",
      "note": "a references section is in the text (p130); its entries are not extracted"
    },
    {
      "kind": "glossary",
      "state": "not-extracted",
      "note": "a glossary section is in the text (p10); its entries are not extracted"
    },
    {
      "kind": "footnotes",
      "state": "found",
      "count": 4
    },
    {
      "kind": "summaries",
      "state": "found",
      "count": 20,
      "note": "20 of 20 sections"
    }
  ],
  "links": {
    "repo": "litlfred/who-iris",
    "branch": "main",
    "dir": "library/10665-331525"
  }
}
